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  i 
ABSTRACT 
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of small B 
lymphocytes in blood, bone marrow, lymph nodes and other lymphoid tissues. CLL is the 
most common leukemia in the Western world. Despite significant advances in understanding 
the pathogenesis, CLL is still a disease with no available cure.  
Receptor tyrosine kinases (RTKs) are a large family of cell surface receptors participating 
in crucial cellular processes including proliferation, differentiation, cell-cell interaction, 
metabolism, signaling, migration and cell survival. More than half of the RTK families are 
overexpressed or mutated in different forms of human cancer. RTKs are multifunctional 
therapeutic targets and novel RTKs in cancer have been pursued extensively as a goal for 
targeted therapies. ROR1 belongs to one of twenty families of RTKs. It is a survival kinase and 
acts as a receptor for Wnt5a protein. 
Gene expression profiling studies have shown that ROR1 was upregulated in CLL patients. 
Characterization of ROR1 expression in CLL and the study of its functional role for possible 
therapeutic targeting was the driving force of this thesis. 
In the first study we investigated the expression pattern of ROR1 in CLL. All CLL patients 
(n=18) expressed ROR1 both at gene and protein levels but none of the healthy donors. CLL 
patients showed a ROR1 surface expression in the range of 36–92%. Western blot analysis 
revealed two ROR1 bands of 105 and 130 kDa. Mutation analysis of the ROR1 gene showed no 
major genomic aberrations. FISH analysis of PBMC from 3 CLL patients showed no 
rearrangement in the 1p region. 
The second study was conducted to examine the effects of siRNAs specifically silencing 
ROR1 and fibromodulin (FMOD) in CLL cells. siRNA treatment induced a specific reduction 
(75–95%) in FMOD and ROR1 mRNA expression. Western blot analysis for ROR1 and 
FMOD demonstrated that the proteins were significantly downregulated 48 h after siRNA 
treatment. Silencing of FMOD and ROR1 resulted in a statistically significant apoptosis of CLL 
cells but not of B cells from normal donors.  
In the third study, five ROR1 monoclonal antibodies were raised against extracellular 
domains of ROR1 to investigate the in vitro apoptotic effects on CLL cells. All five mAbs 
induced apoptosis of CLL but not of normal B cells in the absence of complement or immune 
effector cells. Most effective were mAbs against CRD and KNG, being superior to rituximab in 
vitro. Cross-linking of the anti-ROR1 mAbs using F(ab´)2 fragments of anti-Fc antibodies 
significantly augmented apoptosis. Two of the mAbs induced complement-dependent 
cytotoxicity similar to that of rituximab. 
The fourth study was aimed at investigating ROR1 and ROR2 expression in hematological 
malignancies of lymphoid and myeloid origins. The results showed a statistically significant 
variation in the expression of ROR1 in various hematological malignancies. No expression of 
ROR2 was detected in hematological malignancies tested and PBMC of healthy donors. A 
statistically significant higher expression of ROR1 was detected in progressive compared to 
non-progressive CLL patients. ROR1 expression was shown to be stable overtime. 
In conclusion ROR1 was found to be ectopically expressed in CLL. Given the successful 
history of RTKs targeted therapies in cancer, ROR1 might be a novel potential therapeutic 
target structure in CLL. 
  ii 
LIST OF PUBLICATIONS 
 I. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, 
Ostadkarampour M, Akhondi M, Lagercrantz S, Larsson C, Österborg A, Shokri 
F, Mellstedt H, and Rabbani H. ROR1, a cell surface receptor tyrosine kinase is 
expressed in chronic lymphocytic leukemia and may serve as a putative target 
for therapy. International Journal of Cancer, 123(5):1190-95, 2008. 
 
II. Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Kiaii S, Kokhaei 
P, Österborg A, and Mellstedt H. Silencing of ROR1 and FMOD with siRNA 
results in apoptosis of CLL cells. British Journal of Haematology, 151(4):327-
35, 2010. 
 
III. Daneshmanesh AH, Khan AS, Hojjat-Farsangi M, Jeddi-Tehrani M, Akhondi M, 
Ali Bayat A, Ghods R, Mahmoudi AR, Hadavi R, Österborg A, Shokri F, 
Rabbani H, and Mellstedt H. Monoclonal antibodies against ROR1 induce 
apoptosis of chronic lymphocytic leukemia (CLL) cells. (Submitted) 
 
IV. Daneshmanesh AH, Porwit-MacDonald A, Hojjat-Farsangi M, Jeddi-Tehrani M, 
Pokrovskaja Tamm K, Grandér D, Lehmann S, Shokri F, Rabbani H, Österborg 
A, and Mellstedt H. The receptor tyrosine kinases ROR1 and ROR2 expression in 
hematologic malignancies. (Manuscript) 
 
 
 
 
 
Related Publications: 
A. Mikaelsson E, Danesh-Manesh AH, Lüppert A, Jeddi-Tehrani M, Rezvany MR, 
Sharifian RA, Safaie R, Roohi A, Österborg A, Shokri F, Mellstedt H, and 
Rabbani H. Fibromodulin, an extracellular matrix protein: characterization of its 
unique gene and protein expression in B-cell chronic lymphocytic leukemia and 
mantle cell lymphoma. Blood, 105(12):4828-35, 2005. 
 
B. Rabbani H, Ostadkarampour M, Danesh Manesh AH, Basiri A, Jeddi-Tehrani 
M, Forouzesh F. Expression of ROR1 in patients with renal cancer – a potential 
diagnostic marker. Iranian Biomedical Journal, 14(3):77-82, 2010. 
 
  iii 
LIST OF ABBREVIATIONS 
 
ABC 
ADCC 
AICDA 
Ag 
ALL 
AML 
APC 
ATM 
2-M 
BCR 
BCL-2 
BDB 
BM 
B-NHL 
CAP 
CAR 
CDC 
CHO 
CLL 
CD40L 
CDR 
CHOP 
CML 
CMV 
CNS 
CpG 
CR 
CRD 
DAPK-1 
DLBCL 
ECD 
EGCG 
EGFR 
EMA 
FA 
FC 
FCA 
FCR 
FDA 
FGFR 
FISH 
FLT3 
FL 
FMOD 
Antibody binding capacity 
Antibody-dependent cell-mediated cytotoxicity 
Activation-induced cytidine deaminase 
Antigen 
Acute lymphocytic leukemia 
Acute myelogenous leukemia 
Antigen presenting cell 
Ataxia telangiectasia-mutated 
2-Microglobulin 
B cell receptor 
B cell lymphoma 2 
Brachydactyly B 
Bone marrow 
B-cell non-Hodgkin lymphomas 
Cyclophosphamide, adriamycine, prednisone 
Chimeric antigen receptor 
Complement-dependent cytotoxicity 
Chinese hamster ovary 
Chronic lymphocytic leukemia 
CD40 ligand 
Complementarity-determining region 
Cyclophosphamide, adriamycine, vincrinstine, prednisone 
Chronic myelogenous leukemia 
Cytomegalovirus 
Central nervous system 
Cytosine-phosphoguanine dinucleotides 
Complete response 
Cysteine-rich domain 
Death-associated protein kinase 1 
Diffuse large B-cell lymphoma 
Extracellular domain 
Epigallocatechin-3-gallate 
Epidermal growth factor receptor 
European Medicines Agency 
Fludarabine/alemtuzumab 
Fludarabine/cyclophosphamide 
Fludarabine/cyclophosphamide/alemtuzumab 
Fludarabine/cyclophosphamide/rituximab 
Food and Drug Administration 
Fibroblast growth factor receptor 
Fluorescence in situ hybridization 
Fms-like tyrosine kinase 3 
Follicular lymphoma 
Fibromodulin 
  iv 
FR 
GAS 
GC 
GIST 
HCL 
HEK293 
HER2 
HPV 
IC 
ICD 
IFN 
Ig 
IGFR 
IGHV 
IL 
IWCLL 
KNG 
LDH 
LDT 
LN 
mAb 
MAPK 
MBL 
MCL 
MCL-1 
MFI 
MM 
MRCC 
MuSK 
MZL 
NF-kB 
NGF 
NK cell 
NLC 
NP 
NSCLC 
NTRKR 
OR 
OS 
PARP 
PB 
PC 
PDGFR 
PFS 
PI3K 
PRD 
PTB 
PTM 
Fludarabine/rituximab 
Gamma interferon activation site 
Germinal center 
Gastrointestinal stromal tumours 
Hairy cell leukemia 
Human embryonic kidney 
Human epidermal growth factor receptor 2 
Human papillomavirus 
Immunocytoma 
Intracellular domain 
Interferon 
Immunoglobulin 
Insulin growth factor receptor 
Ig heavy chain V  
Interleukin 
International WORKSHOP on chronic lymphocytic leukemia 
Kringle domain 
Lactate dehydrogenase 
Lymphocyte doubling time 
Lymph nodes 
Monoclonal antibody 
Mitogen-activated protein kinase 
Monoclonal B lymphocytosis 
Mantle cell lymphoma 
Myeloid leukemia cell differentiation protein  
Mean florescence intensity 
Multiple myeloma 
Metastatic renal cell carcinoma 
Muscle-specific kinase 
Marginal zone lymphoma 
Nuclear factor kappa B 
Nerve growth factor 
Natural killer cell 
Nurse-like cells 
Non-progressive 
Non-small-cell lung cancer 
Neurotrophic tyrosine kinase receptor 
Overall response 
Overall survival 
Poly (ADP ribose) polymerase 
Peripheral blood 
Proliferation center 
Platelet-derived growth factor receptor 
Progression-free survival 
Phosphatidylinositol 3-kinases 
Prolin-rich domain 
Phosphotyrosine-binding 
Posttranslational modifications 
  v 
ROR 
ROS 
RRS 
RTK 
SHM 
SH2 
SLL 
SLVL 
SCT 
sIg 
SNPs 
SRP 
sTK 
S/TRD 
TAA 
TCL1 
TCR 
TD 
TGF 
TI 
TK 
TKI 
TRM 
TNF 
t-ROR1 
VEGFR 
XIAP 
ZAP70 
Receptor tyrosine kinase-like orphan receptor  
Reactive oxygen species 
Recessive Robinow syndrome 
Receptor tyrosine kinase 
Somatic hypermutation 
Src homology 2 
Small lymphocytic lymphoma 
Splenic lymphoma with villous lymphocytes 
Stem cell transplantation 
Surface immunoglobulin 
Single nucleotide polymorphisms 
Signal recognition particle 
Serum thymidine kinase 
Serine/threonine-rich 
Tumor-associated antigen 
T cell leukemia/ lymphoma 1 
T cell receptor 
T cell-dependent 
Tumor growth factor 
T cell-independent 
Tyrosine kinase 
Tyrosine kinase inhibitor 
Transplant-related mortality 
Tumor necrosis factor 
Truncated ROR1 
Vascular endothelial growth factor receptor 
X-linked inhibitor of apoptosis protein 
Tyrosine kinase zeta-associated protein 70 
 
 
  vi 
CONTENTS 
Abstract ............................................................................................................................................................. i 
List of publications .......................................................................................................................................... ii 
List of abbreviations ...................................................................................................................................... iii 
 
1 CHRONIC LYMPHOCYTIC LEUKEMIA ............................................................................................. 1 
1.1 Definition ..................................................................................................................................... 1 
1.2 Incidence and epidemiology ...................................................................................................... 1 
1.3 Etiology and risk factors ............................................................................................................ 1 
1.4 Diagnosis ..................................................................................................................................... 2 
1.4.1 Diagnostic criteria ......................................................................................................... 2 
1.4.2 Differential diagnosis .................................................................................................... 2 
1.5 Staging ......................................................................................................................................... 3 
1.6 Prognosis ...................................................................................................................................... 4 
1.6.1 Clinical prognostic factors ............................................................................................ 5 
1.6.2 Biological prognostic factors ........................................................................................ 5 
 1.6.2.1 Serum markers ............................................................................................. 5 
 1.6.2.2 IGHV mutational status ............................................................................... 6 
 1.6.2.3 Surrogate markers ....................................................................................... 6 
 1.6.2.4 Chromosomal abnormalities ....................................................................... 6 
1.7 Pathology and biology ................................................................................................................ 7 
1.7.1 Normal B cell encounter, BCR response and IGHV mutation ..................................... 7 
1.7.2 Genomic aberrations and gene mutations .................................................................... 9 
1.7.3 Epigenetic alterations .................................................................................................... 9 
1.7.4 Microenvironment ....................................................................................................... 10 
1.8 Treatment ................................................................................................................................... 11 
1.8.1 Cytostatic drugs ........................................................................................................... 11 
1.8.2 Monoclonal antibodies ................................................................................................ 12 
1.8.3 Chemoimmunotherapy................................................................................................. 13 
1.8.4 Stem cell transplantation ............................................................................................. 14 
1.8.5 Emerging therapies ..................................................................................................... 14 
2 RECEPTOR TYROSINE KINASES ...................................................................................................... 17 
2.1 Introduction ............................................................................................................................... 17 
2.2 Structure ..................................................................................................................................... 18 
2.2.1 Extracellular region of RTKs ...................................................................................... 18 
2.2.2 Transmembrane region of RTKs ................................................................................. 19 
2.2.3 Cytoplasmic region of RTKs ....................................................................................... 19 
 2.2.3.1 Juxtamembrane domain ............................................................................. 19 
 2.2.3.2 Tyrosine kinase domain ............................................................................. 20 
 2.2.3.3 Carboxyl-terminal tail ............................................................................... 20 
2.3 Activation and regulation of receptor tyrosine kinases ......................................................... 20 
2.3.1 Receptor dimerization ................................................................................................. 20 
2.3.2 Tyrosine kinase autophosphorylation ......................................................................... 22 
  vii 
 
2.3.3 Receptor tyrosine kinases regulation .......................................................................... 23 
 2.3.3.1 Autoinhibition by activation loop of tyrosine kinase domain ................... 23 
 2.3.3.2 Autoinhibition by juxtamembrane domain ................................................ 24 
 2.3.3.3 Autoinhibition by C-terminal domain ........................................................ 24 
 2.3.3.4 Downregulation of receptor tyrosine kinases ........................................... 24 
2.4 Receptor tyrosine kinases and cancer ..................................................................................... 24 
2.5 Targeting receptor tyrosine kinases in cancer ........................................................................ 25 
2.5.1 Therapeutic antibodies ................................................................................................ 25 
2.5.2 Small-molecule inhibitors ............................................................................................ 27 
3 ROR FAMILY OF RECEPTOR TYROSINE KINASES ....................................................................... 28 
3.1 Introduction ............................................................................................................................... 28 
3.2 Structure of ROR1 and ROR2 receptor tyrosine kinases ..................................................... 29 
3.2.1 Extracellular regions of ROR RTKs ............................................................................ 30 
 3.2.1.1 Signal peptide of ROR RTKs...................................................................... 30 
 3.2.1.2 Immunoglobulin-like domain (Ig)  ............................................................. 30 
 3.2.1.3 Cysteine-rich domain (CRD)  .................................................................... 30 
 3.2.1.4 Kringle domain (KNG)  ............................................................................. 31 
3.2.2 Intracellular regions of ROR RTKs ............................................................................. 31 
 3.2.2.1 Tyrosine kinase domain (TKD)  ................................................................. 31 
 3.2.2.2 Serine/threonine-rich (S/TRD) and prolin-rich domains (PRD)  ............. 32 
3.3 ROR expression and function .................................................................................................. 32 
3.4 Aberrant activation of ROR receptor tyrosine kinases ......................................................... 33 
3.4.1 ROR1 overexpression and cancer ............................................................................... 33 
3.4.2 ROR2 genetic disorders and cancer ........................................................................... 34 
3.5 Targeted therapies of ROR receptor tyrosine kinases ........................................................... 35 
4 AIMS OF THE THESIS ......................................................................................................................... 38 
5 RESULTS ............................................................................................................................................... 39 
6 DISCUSSION ......................................................................................................................................... 44 
6.1 ROR1 characterization ............................................................................................................... 44 
6.2 Functional studies of ROR1 ....................................................................................................... 46 
6.3 ROR and hematological malignancies ...................................................................................... 48 
7 CONCLUSIONS AND FUTURE PERSPECTIVES ............................................................................... 50 
8 ACKNOWLEDGEMENTS .................................................................................................................... 52 
9 REFERENCES ....................................................................................................................................... 55 
 
 
 
 
Chronic lymphocytic leukemia 1 
 
1 CHRONIC LYMPHOCYTIC LEUKEMIA 
1.1 DEFINITION 
Chronic lymphocytic leukemia (CLL) is a clonal disease of unkown etiology and is 
characterized by the accumulation of small B lymphocytes with mature appearance in 
blood, bone marrow, lymph nodes and other lymphoid tissues [1]. The B cells in CLL 
express CD19, CD5, and CD23 and also show decreased levels of membrane IgM, IgD, 
and CD79b [2-5]. CLL is known to be a heterogeneous disease and follows an extremely 
variable clinical course with overall survival time after diagnosis ranging from months to 
decades [6, 7]. CLL may stay non-progressive (indolent) for many years without any 
treatment required but there are many patients who will encounter the progressive stage 
of the disease and require treatment for symptoms such as fatigue, disease-related fever, 
lymphadenopathy, splenomegaly and/or bone marrow failure [8]. Despite significant 
advances in understanding the pathogenesis of CLL through years and efficient treatment 
regimens resulting in improved overall survival rates, CLL is still ranked as a disease 
with no available cure. 
1.2 INCIDENCE AND EPIDEMIOLOGY 
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the 
Western world, affecting mainly elderly and accounting for 25-30% of all leukemias [9, 
10]. The incidence is about 2–6 new cases per 100,000 individuals per year [9, 11]. In 
Sweden there are about 500 new cases diagnosed each year [12]. Men are affected by 
CLL more often than women, with a ratio of about 1.5-2:1 [9, 10]. The disease is twice as 
common in males as females. CLL is rarer among Blacks, compared to the Whites and 
much rarer in Asian/Pacific Islanders (75% and 23% that of Whites respectively) [13]. 
The median age at diagnosis in men is 70 years and in women 74 years [14, 15]. About 
one third of patients are diagnosed before 55 years of age [9, 16]. 
1.3 ETIOLOGY AND RISK FACTORS 
The etiology of CLL is unclear. Environmental factors appear not to be a major factor in 
the pathogenesis of CLL [17]. It appears that CLL pathogenesis is related to a genetic and 
familial predisposition and supported by two series of facts. Firstly, CLL is very rare in 
China, Korea and basically absent in Japan. Japanese emigrants maintain the low 
incidence rate within their progeny, thereby excluding an environmental modifier of such 
genetic predisposition [9, 18, 19]. Secondly, there are reports showing a correlation 
between CLL development and a family history of the malignancy [15, 20, 21]. 
Epidemiological studies show that in 5–10% of cases there is a familial susceptibility to 
CLL with two or more individuals affected in the same family [9, 20, 22, 23]. In fact the 
first relatives of CLL patients have an overall risk of 2 to 7 times higher than the general 
population [9, 24]. In a report from the National Cancer Institute Familial Registry, CLL 
2 Chronic lymphocytic leukemia 
 
familial cases were diagnosed at earlier years (mean age diagnosis at 58 years) than 
sporadic cases [15, 25]. There is no difference in survival from diagnosis in familial 
compared with nonfamilial cases of CLL [15, 26]. This familial predisposition is 
accompanied by the genetic anticipation phenomenon, the process in which there is an 
earlier onset and a more severe course of the disease in the offspring of CLL patients [20, 
27-29]. Except for the presentation at earlier age, familial CLL share a high similarity with 
the sporadic CLL cases in clinical, molecular and biological features. 
1.4 DIAGNOSIS 
1.4.1 Diagnostic criteria 
According to the criteria outlined by the International Workshop on CLL (iwCLL), CLL 
can be diagnosed when the following conditions exist: A) The presence of at least 5 × 109 
B lymphocytes/L (5000/μL) in the peripheral blood for a minimum period of 3 months 
[30]. Leukemia cells found in the blood smear are characteristically small, mature 
lymphocytes and can be found mixed with larger or atypical cells or prolymphocytes, 
these cells may comprise up to 55% of the blood lymphocytes [31]. B) CLL cells 
coexpress the T-cell antigen CD5 and B-cell antigens CD19, CD20, and CD23. The 
expression levels of surface immunoglobulins (sIg) including IgM and IgD , CD20, and 
CD79b are characteristically low compared with those found on normal B cells [5, 32]. As 
shown in this thesis, also ROR1 may be added to the list of markers that distinguish CLL 
cells from normal B cells. Each clone of leukemia cells is restricted to expression of 
either kappa or lambda immunoglobulin light chains [5, 30]. The diagnostic criteria for 
CLL is summarized in Table 1. A bone marrow aspirate or biopsy is not required at 
diagnosis in CLL [33]. In contrast bone marrow examination is part of the complete 
remission state, as absence of leukemic involvement of the bone marrow is required for 
this state. 
 
Table 1. Diagnosis criteria for CLL. 
 Presence of ≥5,000 clonal B lymphocytes in the peripheral blood 
 Peripheral blood smear: small, morphologically mature lymphocytes with a narrow border to 
cytoplasm and a dense nucleus lacking discernible nucleoli and having partially aggregated 
chromatin, <55% prolymphocytes, Gumprecht nuclear shadows or smudge cells 
 Immunophenotype: coexpression of the T-cell antigen CD5 and B-cell surface antigens CD19, CD20 
and CD23, levels of CD20 and CD79b are low compared with normal B cells, expression of either 
kappa or lambda immunoglobulin light chains 
Adapted from Cramer P, Hallek M, 2011 [34] 
1.4.2 Differential diagnosis 
Continued elevation of the lymphocyte count demands for a differential diagnosis among 
other lymphoproliferative disorders. The characteristic features discussed above for CLL, 
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differentiate it from mantle cell lymphoma (MCL), hairy cell leukemia (HCL), follicular 
lymphoma (FL) and marginal zone lymphoma (MZL), in particular splenic lymphoma 
with villous lymphocytes (SLVL) (Figure 1). In fact MCL also expresses CD5 but is 
negative for the expression of CD23 and it frequently carries the t(11;14) translocation 
involving the cyclin D1 gene [9]. The other malignancies mentioned are CD5 negative 
and carry a distinct phenotype as detected by flow cytometry [4, 5]. In a disorder very 
similar to CLL, known as small lymphocytic lymphoma (SLL), the tumor is restricted to 
lymph nodes or other tissues without blood involvement. SLL has identical histological 
and immunophenotypic findings to CLL and management of these two malignancies is 
the same [7, 35]. It has been shown that CD5+ monoclonal B cells carrying the distinct 
phenotype of CLL are present in about 3.5% of healthy individuals with normal blood 
counts and can be recognized by flow cytometry [9, 36, 37]. This situation has been named 
monoclonal B cell lymphocytosis (MBL), is age-dependent (seen in >7% of individuals 
over 70 years) and more common in immediate relatives of CLL patients [38, 39]. 
 
 
 
Figure 1. Differential diagnosis of CD19+ lymphocytosis.  
Reprinted from Lancet, volume 371, issue 9617, Dighiero G, Hamblin TJ, “Chronic lymphocytic leukaemia”  
pp. 1017-1029. Copyright (2008), with permission from Elsevier. 
1.5 STAGING 
Two staging systems are presently used to describe the extension and prognosis of CLL, 
the Rai system [40] and the Binet system [41]. These two methods can also be used to 
estimate the starting time of CLL therapy. Originally the number of prognostic groups in 
the Rai classification was 5 but later it was modified to 3 prognostic groups [42] and now 
both these systems describe 3 major subgroups with different clinical outcomes. These 
two staging methods are simple, cheap and are applicable worldwide. Both are dependent 
simply on physical examination and standard laboratory tests and do not require 
advanced diagnostic medical equipments. The Rai and the Binet staging systems are 
summarized in Table 2. 
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Table 2. Rai and Binet clinical staging systems for CLL. 
System Clinical features Median survival, 
year 
Rai stage (simplified 3-stage)   
 0 (low risk) Lymphocytosis in blood and bone marrow >10 
 I and II (intermediate risk) Lymphadenopathy, splenomegaly 
 +/- hepatomegaly 
7 
 III and IV ( high risk) Anemia, thrombocytopenia 0.75 – 4 
Binet group   
 A Fewer than 3 areas of lymphadenopathy; no 
anemia or thrombocytopenia 
12 
 B More than 3 involved node areas; no anemia 
or thrombocytopenia 
7 
 C Hemoglobin <100 g/L, platelets <100 x10 g/L 2-4 
Adapted from Gribben JG, Blood, 2010 [15] 
1.6 PROGNOSIS 
The natural course of CLL is extremely heterogeneous with overall survival time 
stretching from months to decades with a median of about 7.5 years [43]. In contrast to 
other hematological malignancies, age per se is not a prognostic factor due to the fact that 
the biological features and the clinical course of the disease is identical in both young 
(<55 years) and old patients with the overall expectancy of life about 10 years in both 
groups [9]. Prognostic factors efficient in predicting the course of CLL at the initial 
stages of diagnosis are becoming critical for the proper management of CLL patients. 
Prognosis of CLL is dependent on two sets of factors, clinical and biological prognostic 
factors (Table 3 and Figure 2). 
 
Table 3. Prognostic factors in CLL that predict an unfavorable outcome 
Traditional markers 
 Advanced Rai and Binet clinical stage 
 Lymphocytic doubling time <12 months 
 Elevated lactic dehydrogenase 
 Elevated soluble CD23 
 Elevated thymidine kinase 
 Elevated β-2 microglobulin 
 Diffuse pattern of bone marrow infiltration 
Newer markers 
 del(11q) and del(17p) using interphase fluorescent in situ hybridization (FISH) 
 TP53 mutation (with or withour 17p-) 
 Unmutated immunoglobulin heavy chain variable region genes (IGVH genes) 
  VH3.21 gene usage independent of IGVH 
  ZAP-70 ( ≥ 20% positive) 
  CD38 (≥ 30% positive) 
Adapted from Foon KA, Hallek MJ, Leukemia, 2010 [6] 
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1.6.1 Clinical prognostic factors 
The first prognostic markers to supplement the clinical staging methods were based on 
the morphology of CLL cells in blood and bone marrow. The clinical stage of CLL 
diagnosed according to the Rai or the Binet staging systems can be helpful in prognosis 
of the disease. A better prognosis is seen in Rai stage 0 (low risk) and Binet stage A 
compared to the other stages [33]. If the lymphocyte doubling time (LDT) is less than 12 
months it indicates disease progression [44], i.e. decreased progression-free and overall 
survival time [45, 46]. A diffuse bone marrow infiltration pattern correlates with a poorer 
prognosis [47, 48], the relevance of this factor to clinical practice has diminished with 
finding new potent prognostic factors. These prognostic factors seem to be incapable of 
predicting the progression of the disease at initial diagnosis. 
1.6.2 Biological prognostic factors 
Several biological prognostic factors have been identified that in association with the 
clinical parameters may help to better define the patient's prognosis. Extensive research 
resulted in better understanding of the pathogenesis and led to the development of new 
biological markers that predict the prognosis of CLL patients. Several additional markers 
of potential prognostic value have been recently described, such as vitamin D deficiency, 
NK cell G2D receptors/ligands, angiopoetin-2, mcl-1 as well as SNPs. The space and 
focus of this thesis does however not allow to discuss them in detail. Some traditional 
and also some of verified/confirmed biological prognostic factors are discussed below. 
1.6.2.1 Serum markers 
The most important serum markers in CLL patients are serum β2-microglobulin (sβ2m), 
serum thymidine kinase (sTK), and soluble CD23 (sCD23) and are considered among the 
traditional biologic factor for prognosis. β2m is an extracellular protein that is bound 
noncovalently to the α chain of the class I MHC. In CLL, elevated sβ2m levels correlate 
with advanced disease stage, high tumor burden and shorter progression-free (PFS) and 
overall survival [49-51]. Serum thymidine kinase is involved in a DNA synthesis pathway, 
is found in dividing cells and can be measured by radioassay [52]. High levels of this 
enzyme in CLL patients serum is associated with disease progression and advanced stage 
disease [53, 54]. CD23 is a low-affinity receptor for IgE, expressed on mature B cells, 
antigen-presenting cells and platelets. Soluble CD23 serum levels (sCD23) inversely 
correlate with overall survival and disease progression in Binet stage A patients [55, 56]. 
Contrary to other lymphoid malignancies, the level of serum lactate dehydrogenase has 
become less relevant in CLL patients [34, 57] but still there are reports showing elevated 
lactate dehydrogenase (LDH) serum level is associated with shorter survival time for 
CLL patients [58, 59]. 
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1.6.2.2 IGHV mutational status 
The presence or the absence of somatic mutations within the IGHV genes correlate with 
clinical stage of CLL patients and carry an independent prognostic value in CLL. This 
mutation is discussed in detail below (see 1.7.1). A similarity of more than or equal to 
98% of the IGHV gene with germline sequence, i.e. unmutated cases, is associated with 
the aggressive stage of the disease and a shorter median survival time (8 years vs 24 
years) as compared to mutated cases (homology <98%) [60, 61]. It is worth mentioning 
that according to the Swedish CLL guidelines, the influence of IGHV mutational status 
on clinical management of patients is not to the same extent as cytogenetics 
(http://www.swecll.org/Nationella-riktlinjer). 
1.6.2.3 Surrogate markers 
The sequencing of immunoglobulin genes and determination of their mutation status is 
difficult and expensive. The search for parameters that are strongly correlated with IGHV 
mutation is ongoing. CD38 and ZAP70 expressions are among the known surrogate 
markers reported for CLL. CD38 is a surface protein expressed in early B cell 
development and plasma cells [62]. Expression of CD38 in CLL is associated with 
unmutated IGHV and correlated with poor prognosis [60, 63, 64]. Despite all these reports 
, there are still points to be considered, such as no consensus about the best cut-off value 
is reached and also debate exists on the fact that CD38 expression may vary over time 
especially after the initiation of therapy [65, 66]. The 70-kD zeta-associated protein 
(ZAP70) is a signaling protein in the T cell receptor complex, expressed on CLL cells but 
not on normal B lymphocytes and is also thought to have a role in signaling through the 
B cell receptor in CLL cells [67, 68]. Several studies have shown that mutated cases in 
CLL are mostly ZAP70-negative and unmutated cases ZAP70-positive demonstrating an 
aggressive form of the disease and a poor prognosis [67, 69, 70]. In contrast to CD38, 
ZAP70 expression appears to be stable over time. There are reports showing that no 
absolute connection exists between ZAP70 expression and IGHV mutation, with 
discrepancies occurring in up to 25% of CLL cases [71, 72]. The expression of ZAP70 
appears to be a useful predictor of the time to first treatment when compared with the 
expression of CD38 or IGHV mutation status [71, 73]. 
1.6.2.4 Chromosomal abnormalities 
Fluorescence in situ hybridization (FISH) is the most useful clinical method for 
chromosomal analysis in CLL and has significant prognostic importance (see also section 
1.7.2). Deletion of 13q14, deletion of 11q22, trisomy 12, deletion of 17p13 and deletion 
of 6q21 are the most frequent chromosomal abnormalities reported in CLL [74, 75]. 
Deletion of 17q13 results in loss of p53 and is associated with poor response to therapy, 
rapid disease progression and short survival [75, 76]. Deletion of 11q23, resulting in loss 
of the ATM gene, is associated with more aggressive form of the disease and poor 
prognosis [77, 78]. Trisomy 12 does not significantly affect survival as compared to 
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normal karyotype and patients with deletion 13q14 only, have the most favorable 
prognosis [75, 77]. 
 
 
Figure 2. Proposal for the use of 
prognostic factors in clinical practice 
based on the three criteria evidence, 
simplicity and relevance 
 
Reprinted from Nature Reviews Clinical 
Oncology, volume 8, issue 1, Cramer P, 
Hallek M, “Prognostic factors in chronic 
lymphocytic leukemia-what do we need to 
know?” pp. 38-47. Copyright (2011), with 
permission from Nature Publishing Group. 
 
1.7 PATHOLOGY AND BIOLOGY 
Most CLL cells are quiescent and arrested in G0/G1 of the cell cycle and there is only a 
small proliferative compartment. CLL is viewed as two similar entities, mutated and 
unmutated, both of which originate from antigen-stimulated mature B lymphocytes. 
These entities either avoid death through the intervention of external signals or die by 
apoptosis, only to be replenished by proliferating precursor cells. Pathogenic mechanisms 
in CLL involve two kinds of events: external events such as stimuli from the 
microenvironment and antigenic drive and internal events like genetic and epigenetic 
processes. These mechanisms are found to be crucial in the transformation, progression 
and evolution of CLL. 
1.7.1 Normal B cell encounter, BCR response and IGHV mutation 
The interaction of normal mature B cells with their antigens occur in a microenvironment 
characterized by a network of cells, molecules and signals and is mediated through the B 
cell receptor (BCR). The antigen encounter triggers the processes of B cell activation, 
proliferation and differentiation that result in the generation of antigen-specific memory 
B cells and plasma cells [79, 80]. The same mechanism of response to antigenic 
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stimulation is seen in malignant B cells. Each B cell displays a distinct BCR that is 
formed through variable combinations of V, D and J segments for the Ig heavy chain and 
V and J gene segments for the light chain. In addition to the combinatorial diversity of 
different segments, the BCR repertoire is increased by the introduction of somatic 
mutations through the somatic hypermutation (SHM) process during the germinal centre 
(GC) reaction (reviewed in [81]) [1]. SHM is an affinity-maturation mechanism that turns 
a naive B cell expressing low-affinity surface Ig (sIg) to a long-lived, recirculating 
memory B cell that is a high-affinity antibody producer [79, 82]. As mature B 
lymphocytes, CLL cells express BCR on the cell surface, which is encoded by the 
immunoglobulin (Ig) genes. Low expression of the BCR is characteristic of CLL 
lymphocytes [83]. The reason why there is a poor expression of the BCR in CLL remains 
obscure. Except for one report of mutation in CD79B [84], no genetic defects in BCR 
components have been recorded [85, 86]. 
The discovery that 50% of CLL cases have undergone somatic mutation in IGHV gene 
was a major advance in the understanding of CLL [87, 88]. Studies revealed that CLL 
patients can be divided into either unmutated or mutated groups based on the presence or 
the absence of IGHV gene mutations in CLL cells. Unmutated cases are defined as those 
having ≥ 98% similarity of the IGHV gene with the germline sequence while those having 
< 98% homology are defined as mutated. It was also demonstrated that the IGHV 
mutational status is of prognostic significance. In fact, mutated cases have a more indolent 
clinical course and longer survival than the unmutated cases [60, 61]. The IGHV mutational 
status also correlates with a few of other biological prognostic factors such as ZAP70 and 
CD38 expression. Studies have revealed that patients with unmutated IGHV genes exhibit a 
higher expression of ZAP70 and CD38, have shorter telomeres and are genetically unstable 
as compared to mutated cases [60, 74, 89-91]. The activation-induced cytidine deaminase 
(AICDA), a B cell-restricted enzyme required for somatic mutation and isotype switching, 
is also upregulated in unmutated CLL cases [92-94].  
Somatic mutation of IGHV genes does not occur uniformly. Some Ig gene segments 
such as IGHV1-69, for example, consistently carry few mutations as opposed to the 
typically mutated IGHV3-7, IGHV3-23, and IGHV4-34 genes.  
There are structural differences of the BCR between IGHV-mutated and unmutated 
CLLs. IGHV-unmutated CLL cases more frequently show stereotyped rearrangements of 
the V, D and J segments that have very similar complementarity-determining region (CDR) 
3 regions and display stereotyped light chains and biased somatic mutation patterns [95-97]. 
Studies have demonstrated that more than 20% of CLL cases carry stereotyped BCRs and 
in 1% of cases the Igs are nearly identical, suggesting that common antigens are recognized 
in many patients with CLL [98-102]. The observation that a stereotyped BCR, such as 
IGHV3-21, is associated with worse prognosis even if mutated indicates a possible role of 
an unknown common antigen, but still the role of antigen drive in CLL pathogenesis has to 
be clarified [103]. Extensive work is underway trying to define these antigens, which may 
be autoAg or exogenous [104-106] and a picture of CLL as an antigen-driven or partly 
autoimmune disease is emerging. Some of the antigens currently discussed in CLL are 
cytoskeletal proteins vimentin, filamin B and cofilin-1, along with phosphorylcholine-
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containing antigens (eg. Streptococcus pneumonia polysaccharides), cardiolipin and 
proline-rich acidic protein-1 [107].  
Taken together, although the cellular origin of CLL cells has not been finally clarified, 
there is strong evidence that IGHV-mutated CLLs (mostly) stem from antigen-experienced 
post-GC memory B cells [1]. However, the possibility that the IGHV mutated cells might 
derive from B cells that accumulate SHM in a T cell-independent (TI) immune response, 
that does not involve the GC, or during a primary, Ag-independent BCR diversification 
process should also be considered [108]. IGHV-unmutated CLLs also originate from 
antigen experienced B cells that acquire features of memory B cells. Whether these are 
activated conventional naive B cells, CD5+ B cells or marginal zone-like B cells is not 
clear. Either this activation takes place as part of a TI or T cell-dependent (TD) immune 
response is also yet to be understood [1].  
1.7.2 Genomic aberrations and gene mutations 
Contrary to other low-grade B-cell malignancies, translocations are rarely seen in CLL. 
However aberrations resulting in loss or gain of genetic material, appear during the 
course of the disease and are of prognostic significance [9]. The use of fluorescence in 
situ hybridization (FISH) technique has allowed the detection of one or more 
chromosomal abnormalities in more than 80% of CLL patients [75]. The most common 
chromosomal aberrations detected in CLL are deletions of 13q14 and 11q22–q23, 
trisomy 12 and deletion of 17p13 [74, 75]. Deletion of 13q14 occurs in more than 50% of 
CLL cases, making it the most frequent aberration in CLL. Studies have shown this 
deletion actually involves two noncoding microRNA genes, mir15-a and mir-16-1 [109], 
which are believed to take part in controlling antiapoptotic genes in leukemic cells [110]. 
In 10-20% of the cases, 11q22–q23 deletion is seen. The ataxia telangiectasia-mutated 
(ATM) gene is located within the minimal consensus region of chromosome bands 
11q22.3–q23.1 and is affected in almost all cases with del 11q22-q23 [111, 112]. The 
ATM protein kinase is a central component of the DNA damage pathway and mediates 
cellular responses to DNA double-strand breaks. Trisomy of chromosome 12 is detected 
in 10–20% of the cases. Despite being the least common aberration (in less than 10% of 
the cases), deletion of 17p13 is involved with p53 locus and is associated with rapid 
progression of disease, poor response to conventional chemotherapy and short survival. It 
is shown that deletions and mutations in the p53 gene lead to disease progression and 
alternation of sensitivity to chemotherapy drugs in CLL [75]. There are doubts regarding 
stability of cytogenetic changes over time in CLL, so it is important to use the whole 
panel of FISH markers. 
1.7.3 Epigenetic alterations 
The epigenetic mechanisms involve changes in the gene function of the cell without a 
change in the DNA sequence. In normal circumstances, epigenetic changes are important 
for proper development and function of the cell, but in cancer epigenetic aberrations 
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promote uncontrolled growth of the tumor cells [113] and also result in alteration of gene 
function and malignant transformation of cells [114]. Studies have shown that DNA 
methylation leads to transcriptional gene silencing and aberrant DNA methylation plays 
an important role in tumorigenesis. Like other cancers, altered methylation of DNA 
(hypomethylation) has been described for several genes specifically deregulated in CLL, 
such as BCL2 [115] and T cell leukemia/ lymphoma 1 (TCL1) [116]. An analysis of the 
global methylation profile found that 2.5-8.1% of the CpG (cytosine-phosphoguanine 
dinucleotides) islands in CLL samples were aberrantly methylated [117]. Such 
methylation processes are usually associated with stable silencing of the concerned gene 
and it was suggested that a portion of these methylation events confer a selective 
advantage to the malignant cells [117].  
In CLL patients a correlation between the promoter methylation and transcriptional 
silencing of certain genes, such as death-associated protein kinase 1(DAPK1) and ZAP70 
have been found [118, 119]. Being reversible, epigenetic changes in cancer can be suitable 
therapeutic targets. Histone deacetylase inhibitors are among several compounds tested 
on CLL cells in vitro, however in CLL the results have not been convincing enough 
compared to other leukemias [120]. 
1.7.4 Microenvironment 
It is known that CLL cells show prolonged survival in vivo and accumulate in peripheral 
blood, bone marrow and lymphoid organs which could be due to their resistance to 
undergo programmed cell death [2]. The importance of CLL microenvironment is 
understood by the fact that CLL cells rapidly undergo apoptosis when cultured in vitro 
under conditions that support the growth of human B cell lines [121]. This indicates that 
CLL cell resistance to apoptosis depends on external signals rather than being an intrinsic 
feature of the leukemic cells [2, 122, 123]. Moreover, if cocultured in vitro with bone 
marrow-derived stromal cells, fibroblasts, dendritic cells, nurse-like cells (NLC) or T 
cells, CLL cells can be rescued from apoptosis [124-127]. These cells provide a variety of 
survival stimuli for CLL cells, mediated via soluble factors, extracellular matrix 
components and signals derived from cell-cell contact [128]. Despite the fact that CLL 
cells are largely arrested in G0/G1 phase of the cell cycle, there is a small proportion of 
leukemic cells that continue to divide in the proliferation centres (PC) and interact with 
prolymphocytes and paraimmunoblasts [129]. Proliferation centers are focal aggregates of 
variable size found in lymph nodes and to a lesser extent in the bone marrow [130, 131]. 
At these centers, the growth of leukemic cells is favored by T cell help and also by 
interaction with stromal cells. The form of support offered by T and stromal cells is 
different, T cells provide a short-term support while stromal cells provide a long-term 
support, resulting in prolonged survival of tumor cells and consequently the accumulation 
of leukemic cells [124, 132, 133]. Studies have demonstrated the presence of an increased 
number of T cells, mostly being CD4+ T cells that express CD40 ligand (CD40L). The 
interaction between CD40 and its ligand, CD40L synergizes with BCR signaling and in 
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turn induces several anti-apoptotic signaling pathways, including survivin and NF-κB 
[132, 134, 135]. 
1.8 TREATMENT 
Most often CLL patients do not present any symptoms or signs of the disease, they are 
simply identified because of a blood test requested for an unrelated reason. Most of these 
patients will not need treatment and never progress, however, those who do need 
treatment, are usually presented in the same way. A period of watchful waiting until 
features of progression are observed constitutes the standard management of CLL. The 
signs of progression include bulky lymphadenopathy and/or splenomegaly, marrow 
failure or rapid progression of the disease. The criteria for active disease, defined in the 
International Workshop on CLL (iwCLL) guidelines [30], form the basis for treatment 
initiation in both clinical trials and in routine practice (Table 4).  
 
Table 4. International workshop on CLL guidelines for the initiation of treatment 
Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia 
and/or thrombocytopenia. 
Massive (i.e., > 6 cm below the left costal margin) or progressive or symptomatic splenomegaly. 
Massive nodes (i.e., > 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy. 
Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte 
doubling time (LDT) < 6 months. 
Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids or other standard 
therapy. 
Constitutional symptoms, deﬁned as any one or more of the following: 
 unintentional weight loss ≥ 10% in the previous 6 months; 
 signiﬁcant fatigue (i.e., Eastern Cooperative Oncology Group (ECOG) PS ≥ 2; inability to work 
or perform usual activities); 
 fevers higher 38.0°C for ≥ 2 weeks without other evidence of infection; or 
 night sweats for ≥ 1 month without evidence of infection 
Adapted from Hallek M et al, Blood, 2008 [30] 
1.8.1 Cytostatic drugs 
The golden standard procedure for first-line treatment in CLL (monotherapy) for several 
decades has been alkylating agents such as chlorambucil or cyclophosphamide [136]. Up 
to 70% overall response is reached with chlorambucil alone however complete response 
(CR) is only less than 10%. Almost all patients relapse over time, their response to 
salvage therapy is of shorter duration after every relapse and most of them will die from 
disease-related causes. Chlorambucil is only indicated when palliative purposes is the 
goal of treatment [9]. Recently bendamustine, a purine analogue/alkylator hybrid agent, 
was shown to be effective as first line therapy in CLL [137]. Combinations of alkylating 
agents and anthracyclines such as CAP (cyclophosphamide, doxorubicin, prednisone) 
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[138] and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) [139] have 
shown higher response rates than chlorambucil, but with no survival benefits [9]. 
In the 1980s, the front-line treatment model for CLL was changed with the 
introduction of purine-analogues, especially fludarabine. Fludarabine showed to be able to 
prevent the repair of DNA interstrand crosslinks induced by alkylating agents [140]. 
Fludarabine has been the most studied and used drug among other purine-analogues (e.g. 
cladribine and pentostatin). An overall response of 80% and a complete response of 38% 
have been achieved with single agent fludarabine as first-line therapy [141]. Although 
fludarabine demonstrated superior overall response compared to chlorambucil or alkylating 
regimens, no difference in terms of survival could be observed [139, 142].  
Studies showed a synergism between fludarabine and cyclophosphamide and this 
provided a rationale for combining both classes of drugs together [140]. The most widely 
studied combination chemotherapy regimen for CLL is fludarabine plus cyclophosphamide 
(FC) [143]. Randomized trials have compared single-agent fludarabine to the FC 
combination. All these trials demonstrated significantly higher overall response, complete 
response and progression free survival rates for the combination regimen [144-146], but so 
far no survival benefit has been observed. 
1.8.2 Monoclonal antibodies 
Alemtuzumab is a humanized monoclonal antibody (mAb) directed against the CD52 
antigen. CD52 expression is detected on most normal and malignant B and T 
lymphocytes including monocytes and macrophages [147]. Alemtuzumab mechanism of 
action in CLL is thought to be through antibody-dependent cell-mediated cytotoxicity 
(ADCC), complement activation and possibly also by direct apoptosis induction [148]. 
There are many side effects of alemtuzumab due to the widespread expression of CD52, 
the most common adverse effects are prolonged lymphopenia with an increased risk of 
infections [9]. In about 20% of CLL patients, cytomegalovirus (CMV) reactivation occurs 
usually after 3–8 weeks of alemtuzumab therapy and it is recommended that patients 
should be closely monitored. Alemtuzumab is traditionally given through intravenous 
(IV) infusion but acute administration related events could be diminished, if alemtuzumab 
is administrated subcutaneously (SC) without the need of a dose-escalation schedule [149]. 
At first, the efficacy of alemtuzumab was investigated in CLL patients with 
refractory/relapsed disease [150-152], these studies demonstrated an overall response rate 
of 40% in refractory CLL [151, 153] with noticeable effects in CLL patients with deletion 
of 17p [154]. Encouraging results have also been reported in previously untreated patients. 
As first-line treatment, alemtuzumab efficacy was shown in a phase II [155] and phase III 
trials, with phase III trial revealing a significantly higher OR (83% vs 55%), CR (24% vs 
2%) and longer PFS compared to chlorambucil [156].  
Rituximab is a chimeric murine (mAb) directed against the surface antigen CD20. 
CD20 expression is seen on both normal and malignant B cells. This antibody is most often 
used as single agent or combination therapy in relapsed or refractory indolent non-Hodgkin 
lymphomas. Rituximab exerts its cytotoxic activity through complement-mediated lysis, 
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ADCC and direct induction of apoptosis. Several studies in previously untreated CLL 
patients have demonstrated that rituximab as single agent in CLL is inferior to fludarabine 
[157] and also considerably less effective than in follicular lymphoma [158, 159].  
Ofatumumab is a fully human mAb targeting a different epitope on CD20 than the one 
targeted by rituximab and has been demonstrated to induce higher complement-mediated 
CLL cell lysis in vitro [160, 161]. In a recent study, an overall response rate of 50% was 
obtained in refractory CLL [162], leading to approval of ofatumumab by the FDA and by 
the European Medicines Agency (EMA). 
1.8.3 Chemoimmunotherapy 
There has been additional success in managing CLL with a combination regimen of 
cytostatic agents (fludarabine and cyclophosphamide) and monoclonal antibodies. The 
basis for this combination treatment plan was from preclinical evidence showing synergy 
between rituximab and chemotherapeutic agents [163-165]. In some initial studies 
conducted to evaluate the effects of rituximab combined with fludarabine (FR), the 
results were quite promising [166, 167].  
In a randomized phase II trial, the combination of rituximab with fludarabine 
regimens was investigated and demonstrated a higher significant complete remission rate 
for the simultaneous administration of ﬂudarabine and rituximab (FR) (47% CR) as 
compared to (28% CR) of the sequential treatment (F followed by R) [168]. By 
retrospective comparison, the results of this trial were correlated with a previously 
conducted study of 178 untreated CLL patients treated with fludarabine alone [142]. This 
study revealed an advantage in terms of progression-free survival and overall survival 
given by the FR combination compared to ﬂudarabine alone [169].  
In one report, as first-line treatment of CLL patients, the overall response rate of 95% 
and complete remission rate of 70% were reported in the FCR group. In controls treated 
with fludarabine and cyclophosphamide (FC), an overall response rate of 88% and 
complete remission rate of 35% were recorded [170]. A recent data from the first 
randomized trial, fludarabine and cyclophosphamide (FC) versus fludarabine, 
cyclophosphamide and rituximab (FCR), showed higher overall response rate, more 
complete remissions and longer median progression-free survival rate for the FCR treated 
patients [171]. Particularly, this study was able to demonstrate for the first time that a 
specific first-line treatment for CLL resulted in a significantly improved overall survival. 
The percentage of patients alive, in the FCR arm was 87% versus 83% for the FC treated 
patients, three years after randomization. Of significance, in this trial was the fact that a 
population of fairly young and physically fit patients were included.  
Furthermore, patients with deletion of 17p demonstrated the worst prognosis and no 
significant difference in overall survival were noted between the two treatment arms. 
FCR was approved by European Medicines Agency (EMA) as first-line CLL treatment in 
2009. In a phase III study, the combination of alemtuzumab with FC was not successful, 
due to increased toxicity in FCA arm, in seven (7/82) patients the toxicity was fatal [172], 
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whereas another trial on FCA (using a lower dose of alemtuzumab) has been completed as 
planned (results pending). 
1.8.4 Stem cell transplantation 
High complete remissions, including molecular remission, can be achieved by autologous 
stem cell transplantation in CLL patients, but due to the persistent relapse of the disease, 
still there is no definitive cure with this form of therapy [173, 174]. In order to find the 
best strategy regarding stem cell transplantation, there is a need for clinical trials to 
compare autologous or allogenic hematopoietic stem cell transplantation (SCT) and 
chemoimmunotherapy regimens.  
Moreover, due to the advanced age, indolent clinical course in the majority of CLL 
patients and a high (20 to 41%) transplant-related mortality (TRM), SCT can not be 
considered as a treatment option in most cases [175]. European Bone Marrow Transplant 
guidelines provide indications for SCT in CLL, recommending allogeneic SCT for younger 
patients who do not respond or relapse early (<12 months) after ﬁrst-line combination 
chemotherapy or in patients with p53 abnormalities requiring treatment [176, 177].  
1.8.5 Emerging therapies 
The past decade has seen major advances in treatment options for CLL, but still CLL 
remains an incurable disease. At present, the most effective treatment for CLL consists of 
a combination of fludarabine, cyclophosphamide, and rituximab (FCR). In previously 
untreated patients FCR combination therapy results in an overall response rates (ORR) of 
95%, complete remission (CR) rates of 44% and a median progression-free survival 
(PFS) of 52 months [178].  
Despite all these advances, in addition to successive relapse rates, CLL patients have 
also become increasingly resistant to treatment. Therefore, new agents with novel 
mechanisms of action are needed, especially for relapsing CLL patients. Novel mAbs, 
immunomodulating drugs, Bcl-2 inhibitors, protein kinase inhibitors and small molecule 
signal transduction inhibitors are among the emerging therapies discussed in this section 
[179]. 
Lenalidomide is a derivate to thalidomide and belongs to a class of drugs known as 
immunomodulating drugs (IMiDs). Lenalidomide antitumor effects are mediated through 
the inhibition of TNF-alpha and other prosurvival cytokines, T and NK cells activation, as 
well as antiangiogenic activity. In two phase II trials evaluating lenalidomide for treatment 
of patients with relapsed or refractory CLL, the rates for OR were 47% and 32%, 
respectively and CR of 9% and 7%, respectively [180, 181]. 
There are a number of mAbs in preclinical studies and early phases of clinical trials in 
CLL (Table 5). Some of these include mAbs targeting CD19, such as the BiTE Ab 
blinatumomab, CD20 (GA101, veltuzumab, PRO131921), CD80 (galiximab), CD74 
(milatuzumab) and CD40 (dacetuzumab). 
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Lumiliximab is a genetically engineered (macacue variable regions, human constant 
regions) mAb targeting CD23, a transmembrane glycoprotein, inducing several 
antiproliferatives functions including apoptosis [179]. In combination with FCR in a phase 
I/II trial, the OR rate was 65%, with 52% of patients achieving a CR [182]. 
Obinutuzumab (GA101) is a novel third generation fully humanized mAb. The Fc-
region of GA101 is glycoengineered to result in higher affinity binding to the CD20 type II 
epitope [183]. A phase I study showed that GA101 has a comparable safety profile to 
rituximab [184]. The mechanism of action of GA101 seems to be through complement and 
antibody-dependent cell-mediated cytotoxicity [185]. Compared to rituximab GA101 shows 
an elevated ADCC as well as a markedly higher induction of direct cell death in vitro [186]. 
GA101 is able to potently elicit actin-dependent, lysosomal cell death in CLL cells in vitro 
[187]. Trials are now underway to investigate combinations of chlorambucil with novel 
CD20 antibodies (GA101, ofatumumab) in older CLL patients [188]. 
In addition, many small molecule inhibitors are under investigation, including Bcl-2 
inhibitors, such as oblimersen, obatoclax, AT-101 and ABT-263. Oblimersen alone has 
shown modest activity but in combination with FC regimen, the overall survival was 
enhanced compared to FC alone [189].  
Protein kinase inhibitors such as flavopiridol have also been studied in CLL therapy. 
Flavopiridol is a pan-inhibitor of cyclin-dependent kinases and it induces apoptosis by 
downregulation of the anti-apoptotic protein Mcl-1 in CLL [179]. Sixty four patients with 
relapsed CLL, all previously treated with purine analogue therapy, were treated with single-
agent flavoperidol. The rates for OR and CR were 53% and 2% respectively and median 
PFS for all patients was 9 months [190].  
Phosphatidylinositol 3-Kinases (PI3Ks) are a family of intracellular signaling proteins 
that are crucial components of proliferative, differentiation and survival pathways in many 
cells including those of hematopoietic origin. CAL-101 is an inhibitor of the p110δ isoform 
of PI3K, which has an expression pattern largely restricted to cells of hematopoietic origin. 
In a phase I study with CAL-101 and 54 CLL patients enrolled, the results showed that the 
overall response rate was 26% and 80% of CLL patients had a greater than 50% reduction 
in lymphadenopathy [191].  
Autologous T cells can be genetically manipulated to target specific tumor antigens 
and this constitutes an attractive strategy for cancer therapy [192, 193]. Chimeric antigen 
receptors (CARs) combine an antigen recognition domain of a specific antibody with an 
intracellular domain of the CD3-zeta chain or FcγRI protein into a single chimeric protein 
[194]. The limited in vivo expansion of CAR T cells has been a major obstacle to the 
clinical application of this technique [192, 193].  
The CAR–mediated T-cell responses can be further improved by a costimulatory 
domain such as inclusion of the CD137 (4-1BB) signaling domain. This significantly 
increases antitumor activity and in vivo persistence of CARs as compared with the CD3-
zeta chain alone [195]. 
The results of two recent studies show that the engineered T cells expanded more than 
1000-fold in vivo, migrated to bone marrow and for at least 6 months continued to express 
functional CARs at high levels. Toxicity was seen in the form of B cell aplasia in addition 
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to decreased numbers of plasma cells and hypogammaglobulinemia. Moreover, at least 
1000 CLL cells were eradicated by each infused CAR-expressing T cell. Additionally, in 
the blood and bone marrow a CD19-specific immune response was shown by a potent 
antileukemic effect in all three patients examined, accompanied by CR in two of three 
patients with p53-deficient leukemia. Furthermore, a portion of these cells persisted as 
memory CAR+ T cells and retained anti-CD19 effector functionality [196, 197]. 
There are reports on therapeutic approaches for two RTKs expressed in CLL, VEGF 
receptor and Axl RTKs. These targeted therapies along with future role of ROR1 in therapy 
of CLL is discussed in section 3.5 (targeted therapies of ROR receptor tyrosine kinases). 
 
 
Table 5. Newer monoclonal antibodies in clinical development in CLL and related B cell disorders 
Agent Target 
Humanized/ 
chimeric 
Direct  
cell death 
ADCC CDC 
Development 
status 
MDX-1342 CD19 Humanized Yes Yes No Phase 1 
XmAb5574 CD19 Humanized Modest Yes No Phase 1 
Ofatumumab CD20 Humanized Yes Yes Yes Phase 3 (approved) 
GA-101 CD20 Humanized Yes Yes Modest Phase 2 
PRO131921 CD20 Humanized Yes Yes Yes Phase 1/2 
Veltuzumab CD20 Humanized Yes Yes Yes Phase 1/2 
LFB-R603 CD20 Chimeric Yes Yes Yes Phase 1 
Lumiliximab CD23 Primatized Yes Yes Yes Phase 3 
TRU-016 CD37 Humanized Yes Yes No Phase 1 
SGN40 CD40 Humanized Yes Yes No Phase 1/2 
HCD122 CD40 Humanized No Yes No Phase 1 
MDX-1411 CD70 Humanized No Yes No Phase 1 
Milatuzumab CD74 Humanized Yes No No Phase 1/2 
Ipilimumab CTLA-4 Humanized Yes No No Phase 2 
Bevacizumab VEGF Humanized No No No Phase 2 
Adapted from Jaglowski SM et al, Blood, 2010 [198] 
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2 RECEPTOR TYROSINE KINASES 
2.1 INTRODUCTION 
Receptor tyrosine kinases (RTKs) are a large family of cell surface receptors discovered 
more than 20 years ago [199]. These receptors participate in crucial cellular processes, 
such as proliferation, differentiation, cell-cell interaction, metabolism, signaling, 
migration and cell survival [200, 201]. RTKs are divided into 20 different receptor families 
consisting of 58 members (Figure 3) [202]. More than half of these receptor families have 
been reported to be overexpressed or mutated in different forms of human cancer, 
therefore RTKs are considered as targets for cancer therapy [200].  
All RTKs have a similar molecular structure, an extracellular region containing the 
ligand binding domains, a single transmembrane region and an intracellular region with 
conserved tyrosine kinase (TK) domain. Ligand binding results in dimerization of the 
extracellular part and initiation of intracellular signaling cascade which helps to control 
the vital cellular functions of RTKs [203].  
Aberrant RTKs activation such as receptor overexpression, chromosomal 
translocation, gene amplification, mutations and impaired receptor downregulation 
contribute to development of different forms of cancer in humans [204-206]. RTK 
deregulation and association to cancer formation have been reported in more than 30 
RTKs [200]. Mutations and alternations in the structure of RTKs cause these receptors to 
become potent oncoproteins leading to neoplastic transformation [200, 207].  
RTKs are viewed as multifunctional targets and strategies towards the inhibition of 
RTK signaling include monoclonal antibodies and small molecule inhibitors of tyrosine 
kinase activity [208]. Some of the important RTKs families implicated in cancer are 
VEGFR (vascular endothelial growth factor receptor), ErbB/EGFR (epidermal growth 
factor receptor), PDGFR (platelet-derived growth factor receptor), FGFR (fibroblast 
growth factor receptor) and IGFR (insulin growth factor receptor) families. 
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Figure 3. Receptor Tyrosine Kinase Families. 
Reprinted from Cell, volume 141, issue 7. Lemmon MA et al, “Cell Signaling by Receptor Tyrosine Kinases” pp. 
1117-1134. Copyright (2010), with permission from Elsevier. 
 
2.2 STRUCTURE 
Receptor tyrosine kinases structure consist of mainly three distinct regions, an 
extracellular region that binds polypeptide ligands, a transmembrane helix, and a 
conserved cytoplasmic region that possesses tyrosine kinase catalytic activity [209].  
2.2.1 Extracellular region of RTKs 
The extracellular region of RTKs is preceded by a cleavable signal sequence [210]. The 
extracellular part contains the binding sites for RTK ligands. These ligands range from 
soluble factors and extracellular matrix proteins to surface proteins expressed on adjacent 
cells. The extracellular domain may also be involved in the dimerization of RTKs, a 
process critical for the activation of intrinsic tyrosine kinase activity [211]. Most of the 
potential N-linked glycosylation sites are concentrated in the extracellular region [212, 
Receptor tyrosine kinases 19 
 
213]. This domain is characterized by a low degree of sequence conservation. The 
extracellular region of RTKs contains a linear array of discrete globular domains such as 
immunoglobulin (Ig)-like domains, kringle (KNG) domains, fibronectin type III– like 
domains, cysteine-rich (CRD) domains, leucin-rich domains, cadherin-like domains, 
discoidin-like domains and EGF-like domains [209].  
RTKs show structural differences in their extracellular regions with regard to the 
presence or absence of certain motifs. To give some examples, the EGFR extracellular 
domain contains two cysteine-rich regions, the PDGFR extracellular domain consists of 
five immunoglobulin-like repeats and the VEGFR extracellular domain contains seven 
consecutive immunoglobulin-like repeats. The extracellular domains of members of the 
insulin receptor subfamily contain disulfide bridges responsible for the formation of kringle 
domains and leucine-rich motifs [211]. 
2.2.2 Transmembrane region of RTKs 
The transmembrane region of RTKs consists of a hydrophobic segment of 22–26 amino 
acids inserted in the cell membrane. This part of RTKs show a low degree of homology 
even between closely related RTKs. Lack of sequence conservation might suggest that 
specific amino acid residues within the transmembrane segment do not play a specific 
role in signal transfer. The transmembrane domain is flanked by a proline residue at their 
N-terminus and a cluster of basic amino acids in their C-terminus. Such a configuration is 
found in most transmembrane domains of RTKs and probably secures the transmembrane 
region within the lipid bilayer [211, 214, 215]. 
2.2.3 Cytoplasmic region of RTKs 
The cytoplasmic portion of RTKs consists of a juxtamembrane region (just after the 
transmembrane helix), followed by the tyrosine kinase catalytic domain and a carboxy-
terminal region. These regions contain tyrosine residues which are autophosphorylated 
upon ligand binding, regulate catalytic function and also serve as docking sites for SH2 
(Src Homology 2) domain containing proteins.  
2.2.3.1 Juxtamembrane domain 
The juxtamembrane domain is a 41-50 amino acids segment that separates the 
transmembrane and cytoplasmic domains and is not well conserved between different 
families of receptors. However among members of the same family juxtamembrane 
domain shows a high degree of homology. This region may have a function in 
modulation of receptor functions by heterologous stimuli [208, 215, 216]. It probably also 
have a role in signaling suggested by capability to bind specific substrates in a ligand-
dependent manner [208].  
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2.2.3.2 Tyrosine kinase domain 
Of all the regions of RTKs, the tyrosine kinase domain shows the highest conservation 
level. This conserved tyrosine kinase part is not only within the same RTK family, but 
also when compared to other RTKs families [217]. Tyrosine kinase domain is 
evolutionary highly conserved among different species. To maintain a functioning 
receptor signaling, an intact tyrosine kinase domain is of high necessity. Even a single 
lysine mutation in the ATP-binding site can block the receptor ability to phosphorylate 
tyrosine residues thereby completely inactivating the biological function of the receptor. 
This region also contains autophosphorylation sites that are capable of coupling with 
signal-transducing molecules [208, 215, 218]. 
2.2.3.3 Carboxyl-terminal tail  
The carboxyl-teminal tail is RTKs most distal and noncatalytic part. This region has the 
highest degree of heterogeneity in length (70-200 amino acids) and primary structure, 
even among members of the same RTK subclass. The carboxy-terminal tail is thought to 
contain tyrosine residues that are phosphorylated by the activated kinase part. Some 
reports have suggested an important role of C-terminal portion in modulating kinase 
activity [208, 215]. 
2.3 ACTIVATION AND REGULATION OF RTKs 
Receptor tyrosine kinases are inactive, unphosphorylated and monomeric (with the 
exception of insulin growth factor receptor (IGFR) family of RTKs) in the absence of 
ligands and the conformation of the kinase domain is inactive [219]. The cytoplasmic 
juxtamembrane part has autoinhibitory effects on kinase activity of tyrosine kinase 
domain in some of the RTKs [220].  
Upon ligand binding to extracellular region of RTKs, these receptors are activated and 
undergo a series of changes like receptor oligomerization, disruption of the autoinhibitory 
juxtamembrane interaction and autophosphorylation of specific tyrosine residues within the 
activation loop of the kinase domain [203]. Autophosphorylation creates binding sites for 
signaling proteins, recruiting them to the membrane and by doing so activate multiple 
signaling pathways [201]. 
2.3.1 Receptor dimerization 
There is much evidence showing that activation of the kinase domain is ligand–induced 
and is mediated by receptor dimerization [221, 222]. Receptor tyrosine kinases 
dimerization happens either between two identical receptors (homodimerization), or 
between different members of the same receptor family (heterodimerization) [203]. 
Heterodimerization of RTKs is reported to increase the repertoire of ligands recognized 
by each receptor as well as expand signaling pathways diversity recruited by a given 
receptor [223, 224].  
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Until recently RTKs were thought to have a straightforward mechanism for ligand-
induced dimerization, that is interaction of a bivalent ligand simultaneously with two 
receptor monomers and crosslinking them into a dimeric complex [204]. Some of the 
examples for this “ligand-mediated” mode of receptor dimerization are the nerve growth 
factor (NGF)/neurotrophin receptor TrkA, Tie2, Axl and Eph receptors [225-227].  
Dimerization of RTKs is not restricted to the above mode only. There is “receptor 
mediated” dimerization where the ligand actually makes no direct contribution to the dimer 
interface. This is seen in the epidermal growth factor receptor (ErbB/EGFR) family of 
RTKs [228, 229]. The extracellular regions of ErbB receptors contain four domains (I–IV). 
The ligand binds to two distinct sites (on domains I and III) within a single receptor 
molecule. This ligand binding promotes conformational changes in the extracellular 
domain of ErbB receptors, unmasking a dimerization arm in domain II [230].  
In the absence of a ligand, domain II is unavailable to both ligand binding and 
dimerization because it interacts with domain IV to stabilize a “tethered” conformation. 
This tethered conformation has an autoinhibitory effect on ligand binding and dimerization 
processes as it masks dimerization arm of domain II [231-233]. Ligand binding unfolds the 
tether, allowing domain II dimerization arm to interact with a second ligand-bound receptor 
molecule [204].  
This is quite interesting in the sense that ErbB receptors are in fact different in their 
ligand binding capabilities. The ErbB/EGFR family consists of four closely related type I 
transmembrane tyrosine kinase receptors: EGFR/ErbB-1; also known as HER1, ErbB-2 
(HER2), ErbB-3 (HER3) and ErbB-4 (HER4) [201]. There are known ligands for ErbB-1 
and ErbB-4 and these receptors possess active tyrosine kinase domains. ErbB-3 lacks 
tyrosine kinase activity but it can bind to several ligands [224, 234, 235]. ErbB-2 (HER2) 
also has the active tyrosine kinase domain like ErbB-1 and ErbB-4 but is different from 
other members as there is no known ligand for it [230, 234]. In contrast to other members of 
ErbB RTK family, HER2 receptor exists in an active extended (‘open’) conformation and 
is permanently available for dimerization, as a result of this open conformation it does not 
need a ligand for activation (Figure 4) [236].  
Dimerization can also involve a combination of ligand-mediated and receptor-
mediated components, this is particularly seen in KIT and FGFR families [203, 237, 238]. 
Most RTKs dimerization is likely to be one of these three dimerization modes, ligand-
mediated, receptor-mediated or a combination of ligand-mediated and receptor-mediated 
components [204].  
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Figure 4. ErbB receptors. a) Four members of the ErbB family, EGFR, ERBB3 and ERBB4 exist in a 
tethered (‘closed’) conformation in which the dimerization domain is not available to interact with partner 
ERBB moieties in the absence of ligand. ERBB2 exists in an active extended (‘open’) conformation and 
is permanently available for dimerization. b) Conceptualization of the receptor conformational change on 
ligand binding.  
Reprinted from Nature Reviews Cancer, volume 9, issue 7, Baselga J et al, “Novel anticancer targets: revisiting 
ERBB2 and discovering ERBB3”, pp. 463-475. Copyright (2009), with permission from Nature Publishing Group. 
2.3.2 Tyrosine kinase autophosphorylation 
Autophosphorylation of RTKs occur in two ways: cis-phosphorylation (within a receptor) 
or trans (between receptors) phosphorylation. In the first instance, dimerization initiated 
by ligand-binding causes a conformational change in the receptor, facilitating cis-
autophosphorylation. In the second case, there is no conformational change upon ligand-
binding, just a simple proximity effect provides sufficient opportunity for trans-
autophosphorylation to occur [209].  
Receptor tyrosine kinases require two processes for their intracytoplasmic activation: 
a) increase in intrinsic catalytic activity and b) creation of docking sites for recruiting 
downstream signaling proteins. These two processes are accomplished for the majority of 
RTKs by autophosphorylation on tyrosine residues, a consequence of ligand-mediated 
oligomerization.  
The activation loop within the kinase domain is where autophosphorylation of tyrosine 
residues takes place and this result in stimulation of kinase activity and 
autophosphorylation of tyrosines in the juxtamembrane and carboxy-terminal regions. All 
these phosphorylation steps lead to generation of binding sites for modular domains that 
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specifically detect phosphotyrosine in specific sequence contexts. Src Homology 2 (SH2) 
and the phosphotyrosine-binding (PTB) domains are two well-known phosphotyrosine 
binding modules present within signaling proteins [239]. The activation loop in the kinase 
domain contains between one to three tyrosine residues in many RTKs [240].  
There are reports on a number of RTKs, showing that the phosphorylation of these 
tyrosine residues in the activation loop is essential for stimulation of catalytic activity and 
biological function of RTKs. Some of the RTKs families studied in this regard include: 
insulin growth factor receptor (IGFR), fibroblast growth factor receptor (FGFR), vascular 
endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor 
(PDGFR), hepatocyte growth factor receptor (Met) and TrkA [241-246]. Only epidermal 
growth factor receptor (EGFR) is the major exception to catalytic enhancement via 
activation loop autophosphorylation [247].  
2.3.3 Receptor tyrosine kinases regulation 
As receptor tyrosine kinases play critical roles in cellular signaling processes, there is a 
need for their catalytic activity to be under control. The first level of regulation is created 
by the kinase domain itself where the state of phosphorylation directly controls kinase 
activity [248]. Different regions of intracellular domain of RTKs exhibit autoinhibitory 
mechanisms which then help in keeping the catalytic activity of RTKs under firm control. 
A second level of RTKs regulation is achieved by their downregulation. Receptor 
tyrosine kinases after activation by their ligands and conducting their signal transduction, 
are rapidly internalized and degraded helping to quickly terminate the action of the 
ligands. These mechanisms are discussed below.  
2.3.3.1 Autoinhibition by activation loop of tyrosine kinase domain 
One of these autoinhibitory effects comes from the activation loop within the tyrosine 
kinase domain itself. There exists a tight control of catalytic tyrosine kinase activity 
resulting from a mechanism known as cis-inhibition/trans-activation [209]. In this 
concept, each tyrosine kinase domain (activation loop) is exclusively cis-autoinhibited by 
a series of intramolecular interactions specific for its receptor. Ligand binding and 
receptor dimerization promotes trans-phosphorylation of activation loop tyrosine 
residues, which then disrupts the cis-autoinhibitory interactions and promotes receptor 
activation.  
An equilibrium is always present between inactive and active loop conformations of 
the unphosphorylated RTKs [248]. This balance allows cis-inhibition, but at the same time 
permits trans-phosphorylation between ligand induced receptor dimers [200]. The key event 
triggering RTK activation seems to be the release of cis-autoinhibition, following ligand-
induced receptor dimerization. Studies have revealed that insulin growth factor receptor 
(IGFR) was the first receptor to demonstrate RTK autoinhibition in the activation loop of 
their tyrosine kinase domain [249]. Fibroblast growth factor receptor-1 (FGFR1) is another 
example of this cis-inhibition/trans-activation mechanism [250, 251]. 
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2.3.3.2 Autoinhibition by juxtamembrane domain 
Juxtamembrane autoinhibition is a phenomenon where RTKs are cis-autoinhibited by 
components outside their tyrosine kinase domain. In this case, key tyrosines in the 
juxtamembrane region make extensive contacts with different parts of the tyrosine kinase 
domain, including the activation loop and help to stabilize an autoinhibited conformation. 
This event is seen in MuSK [252], Flt3 [220], KIT [253] and Eph family RTKs [254].  
2.3.3.3 Autoinhibition by C-terminal domain  
This form of autoinhibition is seen in Tie2 RTK and possibly in Met and Ron RTKs. In 
Tie2, an inactive conformation is maintained by interaction of a region in the C-terminal 
domain containing tyrosine autophosphorylartion sites with the active site of the tyrosine 
kinase domain, blocking the access of protein substrates to the activate site and thus 
stabilizing the inactive conformation [255]. 
2.3.3.4 Downregulation of receptor tyrosine kinases 
In addition to the regulatory mechanisms discussed above for controlling the tyrosine 
kinase activity of RTKs, another important means of RTKs regulation in cells is their 
downregulation. This process involves ligand-stimulated endocytosis of occupied RTKs 
and ensuing intracytoplasmic degradation of both the ligand and receptor molecules and 
have been studied extensively for ErbB receptor tyrosine kinases [204, 256-259]. 
Endocytosis can happen either through clathrin dependent or clathrin independent 
mechanisms.  
Recent studies have revealed that ubiquitylation of proteins is regulated by the 
phosphorylation process and in turn ubiquitylation regulates the function of a variety of 
protein kinases and phosphatases [260, 261]. Furthermore, the crosstalk between these two 
important posttranslational modifications (PTMs) plays a vital role in regulating protein 
degradation, processing and cellular trafficking [204, 262]. 
2.4 RECEPTOR TYROSINE KINASES AND CANCER  
Oncogenic deregulation seems to be the result of disruption of one or several of the auto 
control mechanisms that secure the normal repression of catalytic domains. More than 
thirty of known RTKs are implicated in different human malignancies. Aberrant tyrosine 
kinase activation increases the survival, proliferation rate and drug resistance of malignant 
cells. It is also responsible for the increase in angiogenesis, invasiveness and metastatic 
potentials of tumors [200, 219]. 
As discussed earlier regulation of tyrosine kinases occurs in multiple levels, so it is not 
surprising that their dysregulation in cancer cells also happens in several ways. The main 
principles for oncogenic transformation of RTKs are a) gain-of-function (GOF) mutations 
or small deletions, b) overexpression resulting from gene amplification and c) genomic re-
arrangements, such as chromosomal translocations. The first important mechanism of 
aberrant tyrosine kinase activation is mutations (gain-of-function) or small deletions that 
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disturb autoregulation of the kinase domain [219]. The examples of mutations in RTKs and 
their link to cancer can be found in many malignancies. One such example is the mutation 
of FLT3 receptors in acute myeloid leukemia (AML). These mutations results in activation 
of tyrosine kinase domain in the absence of the ligand [263]. In another example, point 
mutations and small deletions in the kinase domain of epidermal growth factor receptor 
(EGFR) in non–small-cell lung cancers (NSCLC) increase the sensitivity of the receptor to 
its ligand and causes alternation in receptor signaling [264-266] 
The second mechanism of deregulation of tyrosine kinase is the overexpression of 
RTKs due to possible gene amplifications. Receptor tyrosine kinase overexpression leads to 
constitutive kinase activation by increasing the concentration of dimers. This also results in 
enhanced expression of these receptors as well as availability of specific ligands. Examples 
include overexpression of ERBB2 (HER2/neu) RTK in breast cancer [267, 268], 
overexpression of ROR1 receptor tyrosine kinase in chronic lymphocytic leukemia (CLL) 
[269-271]. 
The third mechanism which is also a common mechanism of oncogenic deregulation in 
hematologic malignancies is the fusion of a receptor or non-receptor tyrosine kinase with a 
partner protein, usually the result of genomic re-arrangements, most often a balanced 
chromosomal translocation. The partner protein has a distinguished feature in a form of a 
domain that causes constitutive oligomerization of the RTK in the absence of the ligand 
binding, thereby contributing to autophosphorylation and activation [219]. A well-known 
example of this mechanism is a reciprocal translocation between chromosomes 9 and 22 
that generates the Philadelphia (Ph) chromosome. At the molecular level, this translocation 
juxtaposes the coding sequences of the bcr and c-abl genes (c-abl gene encodes a non-
receptor tyrosine kinase). This genetic fusion creates an oncoprotein called BCR-ABL, 
with constitutively active tyrosine kinase activity [272]. 
2.5 TARGETING RECEPTOR TYROSINE KINASES IN CANCER  
There are two major ways of targeting RTKs active in malignancies of both 
hematological and solid tumors. Monoclonal antibody therapy and small inhibiting 
molecules have been two successful approaches in cancer treatment strategies. 
2.5.1 Therapeutic antibodies 
One of the important mechanisms in targeting RTKs in cancer is by using antibodies 
against aberrant receptor tyrosine kinases or their ligands. Antibody targeting results in 
disruption of tyrosine kinase signaling through neutralization of ligand, obstruction of 
ligand binding, receptor internalization and degradation and perhaps antibody-mediated 
cytotoxicity.  
Monoclonal antibodies have been developed against different RTKs and their ligands 
in a variety of cancers. Antibodies against RTKs function mainly either as neutralizing 
antibodies binding to activating ligands of RTKs or anti-dimerization antibodies preventing 
homo- and hetero-dimerization of RTKs (Figure 5). 
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The ErbB-2 or HER2 receptor tyrosine kinase is overexpressed in about 30% of 
invasive breast cancers through gene amplification and is associated with a poor prognosis. 
We know that HER2 has no known ligand and trastuzumab which targets HER2 exert its 
function by inhibiting receptor homo- and hetero-dimerization, internalization and 
endocytic destruction, rather than by blocking ligand binding [273, 274]. Trastuzumab is a 
humanized IgG1 mAb and is used for the treatment of metastatic HER2-overexpressing 
breast cancer and shows a 35% response rate in patients with metastatic breast cancer who 
did not receive prior chemotherapy [275-277]. Trastuzumab in combination with cisplatin 
and a fluoropyrimidine is recommended for advanced gastric cancer positive for the human 
epidermal growth factor receptor 2 (HER2/neu) [278]. 
Cetuximab is a chimeric EGFR-specific IgG1 mAb used as second- or third-line 
therapy for the treatment of metastatic colorectal cancer [279] and squamous cell carcinoma 
of the head and neck [280]. Cetuximab functions by inhibiting the binding of activating 
ligand and also by prevention of receptor dimerization leading to disruption of the signal 
transduction cascade [277, 281, 282].  
Panitumumab is a fully humanized IgG2 mAb that is specific for EGFR and like 
cetuximab is used as second- or third-line therapy for the treatment of metastatic colorectal 
cancer [279]. It works by a mechanism similar to cetuximab but in contrast to cetuximab it 
does not promote ADCC [277]. The vascular endothelial growth factors (VEGFs) are 
expressed by many solid tumors and bind to its receptors on the vascular endothelium 
resulting in angiogenesis. Benefit from cetuximab and panitumumab is restricted to patients 
with wild-type K-ras tumors. One of the most important selection criteria for cetuximab 
and panitumumab therapies is the status of K-ras [283]. 
Bevacizumab is a humanized mAb specific for VEGF and it prevents binding of 
VEGF to its receptor and is approved for the treatment of breast [284], colorectal [285] and 
non-small-cell lung [286] carcinomas in combination with cytotoxic chemotherapy [277, 
287]. Bevacizumab is also used in combination with IFN in the treatment of patients with 
metastatic renal cell carcinoma (mRCC) [288]. There are other monoclonal antibodies in 
various stages of clinical testing but not yet approved by the authorities. 
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Figure 5. Receptor tyrosine kinases: sites 
of therapeutic intervention. Neutralizing 
antibodies, which block the bioactivity of 
RTK ligands, RTK-targeted antibodies, 
which either target overexpressed 
receptors or receptor heterodimerization, 
and small-molecule inhibitors of RTK 
kinase activity have been developed to 
interfere with RTK signal transduction. 
Reprinted from Nature Reviews Cancer, 
Volume 4, Issue 5, Gschwind A et al, “The 
discovery of receptor tyrosine kinases: targets 
for cancer therapy”, pp. 361-70. Copyright 
(2004), with permission from Nature 
Publishing Group. 
2.5.2 Small-molecule inhibitors 
Small-molecules inhibitors can translocate through plasma membrane and by interacting 
with the cytoplasmic domain of RTKs inhibit the catalytic activity of the tyrosine kinase 
domain by interfering with the binding of ATP or substrates. Some of the important and 
approved small-molecule agents are briefly mentioned in this section. 
Imatinib is one of the first successful small-molecule inhibitors, it inactivates the 
kinase activity of the BCR–ABL fusion protein in chronic myelogenous leukemia (CML) 
[289, 290]. In addition to BCR–ABL, platelet-derived growth factor receptor (PDGFR) 
receptor tyrosine kinase is also found to be effectively inhibited by imatinib [291]. Imatinib 
acts as a multi-targeted small-molecule inhibitor of other RTKs including KIT which was 
found to have important roles in the pathogenesis of gastrointestinal stromal tumours 
(GISTs) [292]. 
Gefitinib [293] and erlotinib [294] are potent and selective inhibitors of EGFR tyrosine 
kinase activity. Both these small-molecule agents are approved for treatment of EGFR 
expressing cancer non-small-cell lung cancer (NSCLC) [295, 296]. Erlotinib is also 
approved for treatment of advanced pancreatic cancer in combination with gemcitabine 
[297]. 
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3 ROR FAMILY OF RECEPTOR TYROSINE 
KINASES 
3.1 INTRODUCTION 
Receptor tyrosine kinases (RTKs) are important mediators in different cellular processes 
such as proliferation, differentiation, angiogenesis, survival and migration. Interaction of 
a ligand with extracellular domains of RTKs facilitate communication between the cell 
and its environment and lead to initiation of an intracellular signaling cascade.  
The ROR family of RTKs are type I transmembrane proteins and are largely located in 
the plasma membrane [298]. The vertebrate ROR RTKs consist of two structurally related 
family members, ROR1 and ROR2 (formerly known as neurotrophic tyrosine kinase 
receptor (NTRKR1) and (NTRKR2), respectively) [299]. These receptors are evolutionarily 
conserved in invertebrate and vertebrate, including fruit flies, roundworms, sea slugs, 
zebrafish, chickens, frogs, mice, rats and humans.  
The ROR protein extracellular region contains an immunoglobulin (Ig) domain, a 
Frizzled-like cysteine-rich domain (CRD) and a membrane-proximal kringle (KNG) 
domain. Intracellularly, ROR proteins possess a tyrosine kinase (TK) domain and a proline-
rich domain (PRD) straddled by two serine/threonine-rich domains, serine/threonine-rich 
domain 1 and serine/threonine-rich domain 2 (Figure 6) [300]. The characteristic features of 
ROR family of RTKs are the presence of intracellular tyrosine kinase (TK) domains, 
related to those of the Trk-family RTKs, extracellular Frizzled-like cysteine-rich domains 
(CRDs) and membrane-proximal Kringle domains [301-304].  
Many members of ROR family were isolated by polymerase chain reaction (PCR) 
based screens for tyrosine kinase encoding genes. The first ROR family members, two 
human ROR RTK-encoding genes (hRor1 and hRor2) were originally identified by 
polymerase chain reaction (PCR) based screens nearly 20 years ago in a human 
neuroblastoma cell line [300].  
For quite some time, the receptor tyrosine-like orphan receptor (ROR) family of RTKs 
was among a minority of RTKs families, for which the ligand and signaling pathway was 
unknown, giving rise to their orphan nomenclature. Recent studies have revealed a lot of 
information about functions of ROR family of RTKs and in particular have shown that 
ROR proteins are in fact Wnt receptors. We know that dysfunctions of RTKs results in 
severe developmental defects and diseases such as cancer. Human ROR proteins mutations 
and dysregulations are associated with skeletal deformities and leukemia [305].  
The presence of a truncated ROR1 molecule has been reported in human neural tissues, 
which lacks the extracellular and transmembrane parts. This isoform truncated ROR1 (t-
ROR1) was noted in fetal, adult human CNS, leukemia/lymphoma cell lines and in a 
variety of human cell lines derived from neuroectoderm [11]. Most species appear to 
contain two ROR genes. For example, Drosophila, mouse, rat and human genomes all 
contain two ROR genes. In contrast, only a single ROR-encoding gene has been found in 
Caenorhabditis elegans [306]. 
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Figure 6. Structure of ROR 
receptor tyrosine kinases 
(RTKs) in different species. 
Domain organization of ROR 
proteins in human (hROR1, 
hROR2), mouse (mRor1, 
mRor2), C. elegans (CAM-1) 
and Drosophila (dROR). The 
N-terminal extracellular 
domain (ECD) is above and 
the intracellular domain 
(ICD) is below the double 
line representing the plasma 
membrane. 
Reprinted from Trends in Cell 
Biology, Volume 18, Issue 11, 
Green JL et al, “Ror receptor 
tyrosine kinases: orphans no 
more”, pp. 536-44. Copyright 
(2008), with permission from 
Elsevier.  
 
 
 
 
 
ROR orthologs have also been identified in fruit flies (Drosophila melanogaster; dROR) 
[307], roundworms (Caenorhabditis elegans; cam-1) [308, 309], sea slugs (Aplysia 
californica; Apror) [310], zebrafish (Danio rerio; Ror2 and Ror2) [311], chickens (Gallus 
gallus; cRor1 and cRor2) [312, 313], frogs (Xenopus laevis; XRor1 and XRor2) [314], mice 
(Mus musculus; mRor1 and mRor2) [301] and rat (Rattus norvegicus; rRor1 and rRor2) 
[11]. Whereas the CRD, kringle and TK domains are characteristic of all ROR proteins, 
the architecture of the other domains varies between species [305].  
Here in this section of the thesis, I will concentrate mainly on ROR RTKs of 
mammals, with special attention to human ROR1 and ROR2 receptor tyrosine kinases 
structure, function, expression pattern and involvement in human diseases. 
3.2 STRUCTURE OF ROR1 AND ROR2 RECEPTOR TYROSINE 
KINASES 
ROR1 and ROR2 from each species are homologous to one another. Human ROR1 and 
ROR2 (hRor1 and hRor2) share an overall 58% identity in their amino acid sequence. 
This amino acid identity is reported to be 68% within their kinase domains. The degree of 
sequence conservation is higher within the ROR1 and ROR2 subgroups. For example, a 
97% amino acid identity overall is shared between human and mouse ROR1 (hRor1 and 
mRor1). For ROR2 (hRor2 and mRor2) the identity overall is 92% [11, 306]. Murine 
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RORs are the same length as human, except that murine ROR2 (mRor2) is one amino 
acid longer than human ROR2 (hRor2).  
Mammalian ROR proteins have the same domain structure between them; they contain 
extracellular immunoglobulin (Ig), cysteine-rich (CRD) and kringle (KNG) domains, and 
intracellularly they share tyrosine kinase (TK), proline rich and two serine-threonine rich 
domains in addition to their primary sequence homology and similarity in size. ROR 
receptors are evolutionarily highly conserved between different species e.g., human, 
mouse, Drosophila and C. elegans, suggesting important biological functions. 
Human ROR1 is located on chromosomal region 1p31.3 and consists of 937 amino 
acids (908 after cleavage of the signal peptide) with the estimated molecular weight of 
104.28 kDa. Human ROR2 is situated on chromosomal region 9q22 and consists of 943 
amino acids (910 after signal peptide cleavage) with the molecular weight estimated to be 
104.76 kDa. 
As discussed above ROR family of RTKs consist of three regions, an extracellular 
region, a transmembrane region and an intracellular region. The extracellular region contain 
immunoglobulin (Ig), cysteine-rich (CRD) and kringle (KNG) domains, motifs that are 
believed to participate and mediate protein-protein interactions. The intracellular region of 
RORs contain a tyrosine kinase domain, two regions rich in serine and threonine separated 
by a region rich in prolines [306].  
3.2.1 Extracellular regions of ROR RTKs 
3.2.1.1 Signal peptide of ROR RTKs 
ROR family members contain a predicted short signal sequence of approximately 20 
amino acids at their N-termini. The signal peptides of human ROR1 and ROR2 consist of 
29 and 33 amino acids respectively. Signal peptide is quite essential because it directs the 
protein where it should go. If a given protein is for secretion, the signal peptide directs 
the protein to the endoplasmic reticulum where it will grow further and mature for 
secretion. The signal peptide is recognized by the signal recognition particle (SRP) and 
cleaved by the signal peptidase following transport at the endoplasmic reticulum [306, 
315]. 
3.2.1.2 Immunoglobulin-like domain (Ig) 
Immunoglobulin-like (Ig) domain of human ROR1 consist of 106 amino acids residues, 
the corresponding number for ROR2 is 91 amino acids. The precise function of the 
Immunoglobulin-like domain is not known but it might be involved in protein–protein 
and/or protein–ligand interactions. The other possibility for the role of Ig domain might 
be modification of the function of CRD and Kringle domains [316]. 
3.2.1.3 Cysteine-rich domain (CRD) 
ROR proteins extracellular cysteine-rich domain (CRD) is defined by the presence of 10 
conserved cysteines that form five disulfide bridges. Human ROR1 and ROR2 contain a 
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cysteine-rich domain of 135 amino acids each. The cysteine-rich domain (CRD) of ROR 
RTKs is similar to the Wnt binding domain (CRD region) of Frizzled receptors and is 
considered one of the ligand binding motifs of ROR receptor tyrosine kinases, the other is 
thought to be the kringle domain.  
There are studies now indicating that ROR RTKs also bind to Wnt proteins (ligands) 
and act as their receptors [299, 305]. ROR1 and Wnt5a have been shown to physically 
interact with each other and cooperatively activate NF-κB when overexpressed in HEK293 
cells. Survival of CLL cells in vitro is enhanced by Wnt5a, an effect that could be 
neutralized by anti-ROR1 antisera. These findings indicate to the fact that ROR1 functions 
as an oncofetal surface antigen through which Wnt5a activates NF-κB–dependent survival 
signaling in CLL [271]. It is also reported that ROR2 acts as a receptor or co-receptor for 
Wnt5a and the CRD of ROR2 is required for binding to Wnt5a and mediating Wnt5a 
signaling to cell interior [317, 318].  
3.2.1.4 Kringle domain (KNG) 
The membrane proximal kringle domains of ROR1 and ROR2 consist of 80 and 79 
amino acids sequence respectively. It is also highly conserved throughout the ROR 
family RTKs and might function as recognition modules for binding to other proteins 
including Wnt regulatory proteins and possibly ROR ligands [299]. The presence of a 
kringle domain is a nearly diagnostic characteristic of ROR family members as ROR is 
the only RTK family reported to contain the kringle domain with the exception of 
Torpedo MuSK [306]. 
3.2.2 Intracellular regions of ROR RTKs 
3.2.2.1 Tyrosine kinase domain (TKD) 
ROR receptor tyrosine kinases contain 40 amino acids within the kinase domain [240, 
319]. Twenty one amino acid out of the forty consensus amino acids, are absolutely 
conserved among all RTKs studied until now, making this region the highest conserved 
region across different species of not only ROR receptor tyrosine kinases family but also 
in all known RTKs [240].  
Vertebrate RORs show the most prominent changes in the conserved amino acids. 
Seven amino acids in human ROR1 and mouse ROR1 are altered, the corresponding 
number of amino acid alternations for human ROR2 is five and for mouse ROR2 is six. 
Only a single conserved amino acid is altered in each of the invertebrate RORs, in contrast 
to the vertebrate RORs [306]. It was thought that due to numerous changes to highly 
conserved amino acids within mammalian ROR kinase domains, the kinase activity of 
ROR RTKs may have been lost. This has been investigated and despite their lack of several 
amino acids that are highly conserved in RTKs, ROR1 and ROR2 each have kinase activity 
in vitro [300, 301]. 
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3.2.2.2 Serine/threonine-rich (S/TRD) and prolin-rich domains (PRD) 
ROR1 and ROR2 both possess two serine/threonine-rich domains (S/ TRD1) and (S/ 
TRD2) on both sides of a proline-rich domain (PRD) at the C-terminal to the TK 
domains. No similar domains to the S/TRDs or PRDs of the ROR family RTKs have 
been found in any other proteins. ROR1 and ROR2 serine/threonine-rich domains 1 
(S/TRD1s) show a high degree of homology (~67% identity) but the S/TRD2s do not 
exhibit any apparent homology. The proline-rich domains (PRDs) demonstrate a lower 
degree of homology (~30% identity). These cytoplasmic domains are believed to take 
part in the signaling mechanism of the ROR family RTKs by interacting with signaling 
mediators [299]. Within these serine/threonine-rich and proline-rich domains, it is thought 
that there are potential phosphorylation sites and Src homology 2 (SH2) and Src 
homology 3 (SH3) recognition motifs for protein interaction. These motifs might be 
important in ROR mediated signal transduction by regulating association with SH2 and 
SH3 domains of adaptors/signaling molecules [320]. 
3.3 ROR EXPRESSION AND FUNCTION 
The human ROR1 is expressed in fetal heart, lung and kidney and to a lesser extent in 
placenta, pancreas and skeletal muscles [11]. Normal adult tissues including brain, breast, 
testis, ovary, uterus, prostate, lymph node, small intestine, heart, liver, lung, kidney, 
pancreas, adipose tissue, skin, spleen, adrenal gland, amygdala, pituitary gland, placenta, 
bladder, tonsil, stomach, colon, rectum, skeletal muscle, spinal cord and eye were 
investigated for ROR1 protein expression using a commercial polyclonal goat anti-human 
ROR1. No ROR1 expression (expected band of ROR1 ~120 kDa) was detected in 
majority of these twenty eight normal adult tissues except for a very low level of ROR1 
expression in testis, uterus, lung, bladder, and colon [269].  
Moreover, in another study the relative expression of ROR1 mRNA was detected by 
real-time quantitative PCR in a number of normal hematopoietic and non-hematopoietic 
tissues including CD8+ T-cells, CD4+ T-cells, lymph node, tonsil, bone marrow, fetal 
liver, heart, brain, lung, liver, kidney, pancreas, spleen, thymus, prostate, testis, ovary, 
placenta, small intestine, colon, skeletal muscle, fibroblast and adipose tissue. ROR1 gene 
was not expressed at significant levels in normal adult non-hematopoietic tissues apart from 
low levels in pancreas and adipose tissue. Among normal adult hematopoietic it was 
transiently expressed at an intermediate stage of normal B-cell development at a level that 
is similar to that in B-CLL [321]. The human ROR2 is expressed in fetal heart, kidney and 
lung. In adults ROR2 is expressed in the uterus, prostate, ovary, thyroid gland and small 
intestine [316].  
There are studies in mice showing that ROR1 and ROR2 are broadly expressed during 
embryonic developmental stages including skeletal, respiratory and cardiac developments 
as well as neurite extension in central neurons and their expression is tightly downregulated 
after birth [298, 300, 301, 322-324]. To study the functions of mouse ROR1 and ROR2 
receptor tyrosine kinases, mice lacking either of these genes have been generated. ROR1 
mutant newborn mice were similar in size to the wild-type mice and did not exhibit any 
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apparent gross abnormalities, yet after birth these ROR1 mutant mice showed respiratory 
dysfunction and cyanosis and died within 24 hour [316, 323].  
In contrast, ROR2 mutant mice exhibited dwarfism, short limbs and tail and facial 
anomalies. These ROR2 mutant newborns also showed forced respiration and cyanosis and 
died within 6 hour after birth [325, 326]. ROR1 and ROR2 newborn mice died shortly after 
birth because of difficulty in breathing and the reason for this was found to be the 
incomplete expansion of the alveoli in these mice [316, 323, 326]. As ROR1 and ROR2 
genes showed similar expression patterns in the developing face, limbs, heart and lungs 
[298], the absence of seeming morphological abnormalities in ROR1 mutant mice could be 
explained by functional redundancy between ROR1 and ROR2.  
ROR1/ROR2 double mutant mice were generated to find out if ROR1 interacts 
genetically with ROR2 during developmental morphogenesis. Most of ROR1/ROR2 
mutant mice died before delivery showing the process of perinatal lethality. Despite the fact 
that overall appearance of ROR1 mutant mice appeared to be identical to that of wild-type 
mice, ROR1/ROR2 mutant mice exhibited greater ROR2 mutant phenotypes. The limb and 
tail shortening in proportion to the body length and facial anomalies witnessed in ROR2 
mutant mice were more profound in ROR1/ROR2 mutant mice, indicating that ROR1 and 
ROR2 could interact genetically during developmental morphogenesis [316, 323]. 
3.4 ABERRANT ACTIVATION OF ROR RECEPTOR TYROSINE 
KINASES 
The principal mechanisms leading to aberrant RTK activation in human cancers are, 
autocrine activation, chromosomal translocations, RTK overexpression and gain-of-
function mutations. ROR1 aberration in different cancers, both hematological 
malignancies and solid tumors, has been due to the overexpression of this RTK. There are 
so far no studies showing any mutations or chromosomal translocations of ROR1 
receptor tyrosine kinase in any cancer. In contrast ROR2 seems to have mutations as well 
as overexpression as the mechanisms for its aberrant activity. ROR2 mutations have been 
reported in humans and cause skeletal defects anomalies. Several solid tumors also show 
overexpression of ROR2 RTK.  
3.4.1 ROR1 overexpression and cancer 
A gene expression profiling study of chronic lymphocytic leukemia (CLL) in 2001 
revealed down and upregulation of a number of genes in CLL. Among the genes 
upregulated in CLL, there was ROR1 receptor tyrosine kinase with a 43.8-fold increase 
in CLL cells [327]. Since publishing the results of gene profiling study, special attention 
has been directed towards investigating the role of ROR1 in CLL. One important reason 
for the interest in studying the relationship between ROR1 and CLL was the success 
stories of other RTKs involved in other type of cancers and the possibility of targeted 
therapy in these cancers.  
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There were almost three simultaneous studies showing overexpression of ROR1 at the 
gene and protein levels in CLL cells of all patients. Healthy donor B cells, other blood cells 
of healthy donor and normal adult tissues did not express ROR1 [269-271]. The antibody 
binding capacity (ABC) of ROR1 on the surface of B-CLL cells was measured to be in the 
range of 103 to 104 molecules per cell (2,773-7,090 molecules per cell). There was no 
detectable soluble ROR1 protein in >75% of sera from B-CLL patients [269].  
Mutation analysis of cloned extracellular and cytoplasmic kinase domains of the ROR1 
gene showed no major genomic aberrations (mutation or truncation). No difference was 
detected in protein expression of ROR1 comparing IGHV mutated and unmutated cases. 
FISH analysis of CLL patients showed no rearrangement in the ROR1 locus [270]. The 
extracellular domain of ROR1 could bind Wnt5a molecule and coexpression of ROR1 and 
Wnt5a in HEK cells lead to the activation of NF-κB. Additionally, CLL cells viability 
cocultured with Wnt5a-expressing Chinese Hamster Ovary (CHO) cells was significantly 
greater than those cultured with CHO cells alone. This survival advantage was neutralized 
by the addition of antisera against ROR1 [271].  
Acute lymphocytic leukemia (ALL) patients showed overexpression of ROR1 at gene 
level. A similar expression pattern was also observed in ALL cell lines [328, 329]. There are 
reports showing expression of ROR1 at gene and protein levels in mantle cell lymphoma 
and multiple myeloma cell lines [321, 330], in leukemic cells of marginal zone lymphoma 
(MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and 
follicular lymphoma (FL) patients [331]. Additionally, ROR1 was detected at protein level 
in patients with different B-cell non-Hodgkin lymphomas (B-NHL) including 
immunocytoma (IC), mantle cell lymphoma, marginal zone lymphoma and follicular 
lymphoma [332].  
Recently, ROR1 has also been shown to be overexpressed in several solid tumors [333, 
334]. The presence of a truncated ROR1 isoform (t-ROR1) lacking both the extracellular 
and transmembrane parts has also been reported in some leukemia/lymphoma cell lines in 
addition to human neural tissues, fetal and adult human CNS and in a variety of human cell 
lines derived from neuroectoderm [11]. 
3.4.2 ROR2 genetic disorders and cancer 
Mutations in the human ROR2 gene cause two well characterized skeletal defects, 
recessive Robinow syndrome (RRS) [335, 336] and dominant brachydactyly B (BDB) 
[337, 338]. Recessive Robinow syndrome (RRS) is characterized by short-limbed 
dwarfism and brachydactyly and is caused by loss-of-function mutation of ROR2. 
Additionally these patients exhibit abnormal morphogenesis of face and external 
genitalia, segmental defects of the spine and rib fusions [339-342]. ROR2 mutations in 
recessive Robinow syndrome are in fact missense, nonsense, and frameshift mutations in 
CRD, kringle and kinase domains of ROR2 RTK, suggesting reduced or eliminated 
functions. The second skeletal disorder caused by mutations in ROR2 gene is 
brachydactyly B (BDB), inherited as an autosomal dominant disorder. Affected patients 
show hypoplasia/aplasia of distal phalanges and nails [343, 344]. Brachydactyly type B is 
ROR family of receptor tyrosine kinases 35 
 
thought to be caused by specific mutations in ROR2 gene resulting in truncation of 
ROR2 either before or after the kinase domain. 
ROR2, has been shown to be overexpressed in squamous cell carcinoma [345], 
malignant melanoma [346], osteosarcoma [347], renal cell carcinoma [348], prostate and 
gastric cancers [349, 350]. ROR2 was not detected in CLL and white blood cells of normal 
donors [269]. 
3.5 TARGETED THERAPIES OF ROR RECEPTOR TYROSINE 
KINASES 
RTKs are considered as multitarget proteins and strategies towards the inhibition of 
RTKs signaling include monoclonal antibodies and small molecule inhibitors of tyrosine 
kinase activity. A number of therapeutic mAbs used in oncology are summarized in Table 
6. Several studies have revealed the presence of two other RTKs expressed in CLL, 
VEGFR and Axl, in addition to ROR1. Additionally studies have indicated that CLL cells 
are capable of secreting VEGF spontaenously, mainly the isoforms VEGF165 and 
VEGF121 [351, 352] and constitutively express activated VEGF-R1 and VEGF-R2 .These 
observations might indicate that the apoptosis defect of CLL cells is partly mediated 
through an autocrine feedback loop involving VEGF [352]. Moreover, most of studies 
showed a positive correlation between the level of VEGF receptors on the cell surface 
and shorter survival in CLL patients [353]. Recently another RTK, Axl has been described 
to be constitutively phosphorylated in most CLL B cells [354].  
Targeted therapies in the form of mainly small inhibiting molecules and to a lesser 
extent mAbs have been described for VEGF receptors in CLL. There are reports 
demonstrating utilization of four tyrosine kinase inhibitors (TKIs) in targeting VEGFRs 
[355-358]. Vatalanib and Pazopanib, two of these TKIs are specific inhibitors of VEGF 
receptors. Furthermore, these two TKIs could induce apoptosis of CLL cells both in vitro 
and in vivo (mice grafted with the CLL-like cell line JVM-3). Additionally there was a 
decrease in phosphorylation and downregulation of the antiapoptotic proteins XIAP and 
Mcl-1 [357].  
In a phase II clinical trial three distinct anti-VEGF therapies were tested for patients 
with relapsed/refractory CLL. Between 2005 and 2008, 46 patients were recruited to trials 
of single-agent anti-VEGF antibody (bevacizumab, n=13) or one of two RTK inhibitors 
(AZD2171, n=15; sunitinib malate, n=18). A median of two cycles of bevacizumab, 
AZD2171, or sunitinib malate were given to patients and all patients completed the 
treatment course. However, no complete or partial response was detected and due to lack of 
efficacy all three trial were closed prematurely. In conclusion these studies demonstrated 
that single-agent anti-VEGF therapy has minimal effect for patients with 
relapsed/refractory CLL [356].  
Furthermore, in another study sorafenib, a multikinase inhibitor induced apoptosis in 
primary CLL cells. Sorafenib-induced apoptosis led to downregulation of Mcl-1 and 
activation of caspase-3 and -9, indicating involvement of the cell intrinsic apoptotic 
pathway. Additionally bevacizumab failed to induce apoptosis in CLL cells, suggesting that 
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sorafenib might induce apoptosis irrespective of VEGF signaling [358]. A green tea 
component, epigallocatechin-3-gallate (EGCG) is a known TKI. The effect of this TKI on 
primary CLL cells showed apoptosis of the cells in addition to caspase-3 activation and 
PARP cleavage. Moreover, EGCG suppressed Bcl-2, XIAP and Mcl-1 [355].  
A recent study demonstrated that targeting Axl RTK by a Src/Abl kinase inhibitor, 
bosutinib (SKI-606) or a specific-inhibitor of Axl (R428), leads to a potent induction of 
CLL cell apoptosis in a dose- and time dependent manner [354]. 
As far as ROR1 is considered there is only one study published with regard to targeted 
therapy of this RTK in CLL. Recently, a report has described the generation of a panel of 
mAbs in chimeric rabbit/human Fab and IgG1 formats selected by phage display. These 
antibodies were tested for their ability to mediate ADCC, CDC and internalization. The 
mAb with the highest affinity and slowest rate of internalization was the only mAb that 
mediated a weak ADCC, however no CDC or direct apoptosis induction was detected by 
these mAbs. Furthermore, the internalization data suggested that ROR1 might a suitable 
target for the delivery of cytotoxic loads by antibody-drug conjugates and immunotoxins 
[330]. 
This thesis includes a study (paper III) where we generated five mouse mAbs against 
peptides of extracellular Ig, CRD and KNG domains of ROR1. ROR1 mAbs could 
specifically recognise ROR1 protein on surface of CLL cells. Three functional assays i.e. 
direct induction of apoptosis, cross-linking of the surface bound ROR1 mAbs as well as 
complement in lysis were utilized and compared with murine and chimeric anti-CD20 
(rituximab) mAbs, respectively. ROR1 mAbs were capable of inducing apoptosis using all 
the three functional assays. Different antibodies varied in their percentages of apoptosis, 
these findings are discussed extensively in the result and discussion sections. There was no 
clear correlation between ROR1 expression and apoptosis. Moreover, antibodies alone 
against the CRD and KNG regions had the highest cytotoxic capability. In conclusion we 
targeted CLL cells with specific antibodies against different regions of extracellular domain 
of ROR1 and by doing so, our ROR1 mAbs induced apoptosis and this resulted in cleavage 
of PARP. Furthermore, by producing fully human ROR1 mAbs capable of killing CLL 
cells, we might be able to look for a new way of targeted therapy of CLL. Additionally, our 
preliminary results indicate that ROR1 specific small inhibiting molecules are effective in 
apoptosis induction in primary CLL cells (data to be published). In summary, mAb therapy 
and tyrosine kinase inhibition might be possible targeted therapies in CLL. 
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Table 6. Therapeutic monoclonal antibodies used in oncology 
 
Reprinted from Nature Reviews Immunology, volume 10, issue 5, Weiner LM et al, “Monoclonal antibodies: 
versatile platforms for cancer immunotherapy”, pp. 317-327. Copyright (2010), with permission from Nature 
Publishing Group. 
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4 AIMS OF THE THESIS 
 
 
Paper I 
To investigate the expression of ROR1 in CLL and normal controls. 
 
 
Paper II 
To study the effects of siRNA silencing of ROR1 and FMOD in CLL cells. 
 
 
Paper III 
To generate mouse anti-ROR1 monoclonal antibodies inducing apoptosis of CLL cells. 
 
 
Paper IV 
To study ROR1 and ROR2 expression in hematological malignancies of lymphoid and 
myeloid origins.  
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5 RESULTS 
 
PAPER I 
ROR1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic 
leukemia and may serve as a putative target for therapy 
Int J Cancer. 2008, 123(5):1190-95 
 
Gene profiling studies in 2001 showed downregulations and upregulations of many genes 
in CLL, among them a 43.8-fold increase of ROR1 in CLL cells. This study was 
desgined to investigate the expression pattern of ROR1 in CLL and healthy donors both 
at the gene and protein levels. ROR1 is a member of the receptor tyrosine kinase (RTK) 
family. ROR1 receptors are cell surface receptors participating in signal transduction, 
cell–cell interaction, regulation of cell proliferation, differentiation, cell metabolism and 
survival. ROR1 is highly conserved between species, e.g. human, mouse, drosophila and 
C.elegans suggesting important biological functions and is normally expressed in heart, 
lung and kidneys in adult humans and to a lesser extent in the placenta, pancreas and 
skeletal muscles.  
PBMC of all CLL patients (n=100) expressed ROR1 at the mRNA level, no expression 
of ROR1 was detected in healthy donor PBMC (n=10), normal B cells (n=6), normal T 
cells (n=3), or enriched blood granulocytes (n=10).  
Protein expression of ROR1 was analyzed by Western blot as well as flow cytometry. 
Our N-terminal and C-terminal ROR1 antibodies detected two ROR1 specific bands of 105 
and 130 kDa in CLL samples (n=18). ROR1 commercial antibody detected only the 105 
kDa band. No band was seen in healthy controls (n=10). 
Using ROR1 commercial polyclonal antibody, surface expression of ROR1 in 
progressive (n=9) and non-progressive (n=9) was detected by flow cytometry. The 
frequency of CD19+ CLL cells expressing ROR1 varied 71 ± 5% (mean ± SEM) (range: 
36–92%). Healthy donor B cells (n=10) did not express ROR1.  
PMA/ionomycin could not further activate CLL cells and tonsil B cells due to their 
constitutive ROR1 mRNA expression but induced gene expression of ROR1 in normal B 
and T cells.  
Mutation analysis of cloned extracellular and cytoplasmic kinase domains of the ROR1 
gene was performed in 10 CLL patients and showed no major genomic aberrations. FISH 
analysis of PBMC from 3 CLL patients showed no rearrangement in the 1 p region. Bone 
marrow cell analysis from 4 CLL patients showed no abnormality at the ROR locus.  
In conclusion our results indicate that ROR1 is overexpressed in CLL patients both at 
gene and protein leves but not in healthy donors. RTKs might be interesting targets for 
cancer therapy and ROR1 could be a potential candidate structure for targeted therapy 
using monoclonal antibodies and small inhibiting molecules. 
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PAPER II 
Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells 
Br J Haematol. 2010, 151(4):327-35 
 
The receptor tyrosine kinase ROR1 and small leucine rich proteoglycan Fibromodulin 
(FMOD) are upregulated in chronic lymphocytic leukaemia (CLL) cells. Small 
interfering RNA (siRNA) can specifically interfere with the expression of any given 
gene. In this paper we wanted to see if siRNAs transfection of CLL cells will lead to 
downregulation of ROR1 and FMOD gene and protein levels and if so what would be the 
functional effect of this downregulation.  
The real-time PCR results demonstrated that the transfection of CLL cells with siRNA 
constructs silenced ROR1 and FMOD expression by (75–95%). There was no 
downregulation of the housekeeping gene after transfection period of 24 h.  
After 48 h of siRNA treatment, Western blot analysis demonstrated that ROR1 and 
FMOD proteins were significantly downregulated. The corresponding 105 kDa and 59 kDa 
bands of ROR1 and FMOD were absent in CLL cells transfected with ROR1-specific 
siRNA as compared to untransfected and control siRNA- transfected CLL cells. 
Silencing of FMOD and ROR1 resulted in a statistically significant apoptosis of CLL 
cells but not of healthy donors PBMC (enriched B and T cells). Time kinetics indicated that 
apoptosis was noted as early as 4 h after transfection and was continuing at the end of 48 h. 
Four FMOD + ROR1+ human fibroblast cell lines were tested for apoptosis induction 
following siRNA transfections. Only one of these cell lines, HFFF-PI 6 demonstrated 
induction of apoptosis. 
In summary we have shown that ROR1 and FMOD could be downregulated at gene 
and protein levels by specific ROR1 and FMOD siRNAs. This downregulation resulted in 
induction of apoptosis of ROR1 and FMOD but not healthy B and T cells. These results 
suggest that ROR1 and FMOD are implicated as factors for survival of CLL cells. 
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PAPER III 
Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic 
leukemia (CLL) cells. (Submitted) 
 
In this paper the aim was to generate monoclonal antibodies against the extracellular 
domains of ROR1 capable of detecting surface expression of ROR1. Our intention was to 
have functional ROR1 antibodies to test apoptotic effects of these monoclonal antibodies 
on CLL cells in vitro. ROR1 is highly conserved in human, mouse, Drosophila and C. 
elegans suggesting crucial biological fuctions. ROR1 consists of an extracellular part 
including an immunoglobulin (Ig) -like domain, a cystein-rich domain (CRD) and a 
kringle (KNG) domain as well as an intracellular tyrosine kinase and a proline-rich 
domain. ROR1 is constitutively phosphorylated in CLL. ROR1 siRNA transfection also 
induced specific apoptosis of CLL cells.  
Five ROR1 monoclonal antibodies were raised against extracellular domains of ROR1. 
One was against the Ig domain, Ig (3B8) MAb, two against the CRD domain, CRD (1C11) 
and CRD (1D8) MAbs and two against the KNG domain, KNG (4C10) and KNG (4A7) 
MAbs. For specificity controls HeLa cells were transfectred with ROR1 gene construct 
plasmid. In Western blot all five MAbs recognized specifically a band of 100-105 kDa. No 
band was detected in untransfected cells.  
ROR1 surface expression was detected by flow cytometry using all 5 ROR1 
monoclonal antibodies in CLL patients (n=20). The frequency of ROR1+ /CD19+/CD5+ 
cells for each of the ROR1 monoclonal antibodies were as the following. Ig (3B8): 92 ± 1% 
(mean±SEM) (range: 77-98%); CRD (1C11): 94 ± 1% (72-98%); (CRD (1D8): 88 ± 2% 
(72-94%); (KNG (4A7): 93 ± 1% (74-98%); KNG (4C10): 94 ± 1% (84-99%). No 
expression of ROR1 in B cells of healthy donors was detected. Patients with progressive 
disease demonstrated a significantly higher proportion of ROR1+ CLL cells as compared to 
non-progressive patients. Ig (3B8), CRD (1C11) and KNG (4A7) MAbs stained a 
significantly higher (p<0.05 – p<0.01) frequency of ROR1+ cells in unmutated CLL 
patients compared to the mutated CLL patients. This was not the case for the other two 
ROR1 MAbs. 
Apoptosis induction was measured by Annexin V assay in PBMC from CLL patients 
(n=20) and healthy donors (n=8) using all five ROR1 MAbs. Based on time-kinetics 
experiments the 18 h incubation time was chosen for incubation of antibodies with CLL 
and healthy cells. All ROR1 MAbs alone induced apoptosis of the CLL cells of all patients. 
The differences compared to CLL cells with no antibody or isotype controls were 
statistically significant (p<0.0001). No apoptosis of normal PBMC was detected. CRD 
(1C11), CRD (1D8) and KNG (4C10) MAbs were the best to induce apoptosis of CLL 
cells. These three MAbs (1C11, 1D8, 4C10) were also more effective in apoptosis 
induction than the murine (LT-20) or the chimeric (rituximab) anti-CD20 MAb (p<0.0001). 
There was no relation between the frequency of ROR1+ CLL cells and direct apoptosis.  
Cross-linking of the anti-ROR1 MAbs using F(ab´)2 fragments of anti-Fc antibodies 
significantly augmented apoptosis. Two of the MAbs induced complement-dependent 
cytotoxicity similar to that of rituximab. 
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Western blot analysis indicated PARP protein cleavage of CLL cell lysates undergoing 
apoptosis. All five anti-ROR1 MAbs induced a PARP cleavage product of 85 kDa. 
In summary, we describe the generation, staining pattern and cytotoxicity of a panel of 
mouse MAbs against ROR1. The identified functional epitopes of ROR1 in CLL will be 
further utilized in the development of human antibodies against ROR1 for clinical trials. 
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PAPER IV 
The receptor tyrosine kinases ROR1 and ROR2 expression in hematologic 
malignancies. (Manuscript) 
 
In this study ROR1and ROR2 expression in hematological malignancies of lymphoid and 
myeloid origins was investigated. ROR1 monoclonal antibodies were raised against the 
extracellular part of ROR1 and commercially available ROR1 and ROR2 polyclonal 
antibodies were used for this study. ROR1 expression pattern during progression of the 
CLL disease was also studied. 
ROR1 and ROR2 are cell surface receptors, containing an immunoglobulin-like (Ig) 
domain, a cysteine-rich (CRD) domain and a kringle domain (KNG) in their extracellular 
portion. The intracellular region consists of a kinase-like domain followed by alternating 
regions of serine-threonine and proline-rich motifs. ROR1 is considered a potent survival 
kinase and of importance during embryogenesis and organogenesis. ROR1 is not expressed 
in normal adult lymphoid and non-lymphoid tissues with the exception for adipose tissue. 
ROR2 is involved in the early formation of the chondrocytes and important for cartilage 
and growth plate development. ROR2 deficiency results in 2 skeletal abnormalities, 
Robinow Syndrome and Brachydactyly Type B. No such abnormalities are reported for 
ROR1. 
The results of this study showed a statistically significant variation in the expression of 
ROR1 in various hematological malignancies as compared to controls (no expression of 
ROR1 in PBMC of healthy donors or “reactive” lymph nodes). In flow cytometry, 24/24 of 
chronic lymphocytic leukemia (CLL) cases were positive for ROR1 surface expression 
range of 79-91%, 9/9 mantle cell lymphomas (MCL) (13-93%), 1/1 hairy cell leukemia 
(HCL) (91%), 8/8 marginal zone lymphoma (MZL) (28-76%), 11/11 diffuse large B-cell 
lymphoma (DLBCL) (30-81%), 20/30 follicular lymphoma (FL) (1-89%), 18/23 acute 
lymphoblatic leukemia (ALL) (1-87%), 19/24 acute myelogenous leukemia (AML) (1-
95%), 14/14 chronic myelogenous leukemia (CML) (22-80%) and 14/14 multiple myeloma 
(MM) (36-83%).  
Two cell lines reported to be positive for ROR2, K-562 (a Human 
erythromyeloblastoid leukemia cell line) and HeLa (a cervical cancer cell line) were used 
as controls. No expression of ROR2 was detected in hematological malignancies. PBMC 
from healthy donors did not show any expression of ROR1 and ROR2. A statistically 
significant higher expression of ROR1 was detected in progressive compared to non-
progressive CLL patients (n=7). ROR1 was shown to be stable overtime in stable CLL 
patients (n=5). 
In summary we report the surface expression of receptor tyrosine kinase (ROR1) in all 
hematological malignancies tested, both of lymphoid and myeloid origins. No expression 
of ROR1 and ROR2 was detected in normal donors and reactive lymph nodes. Non-
progressive and progressive patients showed a statistically significant difference in 
expression of ROR1. ROR1 expression was constant during the course of CLL disease. 
Own generated monoclonal antibodies detected a significantly higher expression of ROR1 
than commercial polyclonal antibodies. 
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6 DISCUSSION 
6.1 ROR1 CHARACTERIZATION 
Gene expression profiling of CLL cells has revealed downregulations and upregulations 
of hundreds of genes with various chromosomal localizations. These gene transcripts 
were more prominent in CLL samples compared to other B-cell malignancies and normal 
B cells. However the mutated and unmutated CLL cases showed equal abundance of the 
gene transcripts [327, 359]. Among upregulated genes in CLL, there was a 43.8-fold 
increase of the orphan receptor tyrosine kinase (RTK) ROR1. ROR1 is a transmembrane 
protein located in plasma membrane with a protein size of 105 kDa, localized at 
chromosome 1p31.3 and its structure consists of an extracellular region, a single 
transmembrane region and an intracellular region [300]. It is interesting to know that 
vascular endothelial growth factor receptor (VEGFR) was the first RTK reported in CLL 
[351, 352] and ROR1 the subsequent [269-271]. 
Surprisingly, the ligand for ROR1 was not known until recently and hence the 
nomenclature, orphan receptor tyrosine kinases (ROR1 and ROR2). Studies demonstrated 
that Wnt molecules such as Wnt5a might be a possible ligand for ROR1/ROR2 by 
interacting with the ligand binding motifs of cysteine-rich (CRD) and kringle (KNG) 
domains of ROR family members [271, 317], further suggesting that ROR1/ROR2 could act 
as receptors for Wnt family proteins [305].  
Wnt signaling pathways are reported to have a vital role in cellular processes such as 
cell-to-cell interaction, differentiation and morphogenesis in embryonic development. 
Deregulation or aberrant function of Wnt signaling is found in many types of cancer, 
developmental defects and inherited diseases [360]. ROR1/ROR2 are reported to have a 
crucial function in the non-canonical Wnt signaling [299, 314, 317]. 
The extracellular domain of ROR1 could bind Wnt5a molecule and coexpression of 
ROR1 and Wnt5a in HEK cells lead to the activation of NF-κB. Additionally, CLL cells 
viability cocultured with Wnt5a-expressing Chinese Hamster Ovary (CHO) cells was 
significantly greater than those cultured with CHO cells alone. This survival advantage was 
neutralized by the addition of antisera against ROR1 [249]. 
Studies have shown that several Wnt genes are highly expressed in CLL [361] and high 
levels of Wnt5a secretion have also been detected in several hematological malignancies 
[362, 363]. Stromal cells producing Wnt proteins support the survival of CLL B cells [364]. 
Furthermore, Wnt proteins secreted by both cancer cells and stromal cells, might act as 
growth factors for malignancies in an autocrine or paracrine manner [365, 366]. It may be 
postulated that Wnt5a might be a growth and survival factor for CLL supporting survival of 
leukemic B cells. 
ROR1 signaling events are poorly understood, but there are reports showing Wnt 
binding to ROR1/ROR2 receptors results in a sequence of molecular events, involving 
ROR phosphorylation, activation of PI3K, Cdc42 and MKK7, further leading to 
cytoskeletal changes and/or JNK-mediated phosphorylation of the transcription factor 
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ATF2 [367-369]. Besides, other putative components of the ROR1/non-canonical Wnt 
pathway, specially Vangl2, and Dvl2 were reported to be involved with ROR1 expression 
in CLL [370]. 
Moreover, it is known that STAT3 is constitutively phosphorylated in CLL [371]. 
Phosphorylated STAT3 binds to promoter regions of ROR1 and VEGFR leading to 
activation and by so inducing production of ROR1 and VEGFR proteins in CLL [355, 372]. 
STAT3 could also induce expression of Wnt5a [342]. STAT3 activation is reported for 
various solid and hematologic tumors and related to anti-apoptotic mechanisms and growth 
stimulation of the malignancies [373].  
ROR1 is spontaneously expressed at the gene and protein levels of the leukemic cells 
in all CLL patients but not in normal peripheral blood leukocytes (paper I) and this was 
further supported by other reports [269, 271]. Additionally a uniform high expression in both 
IGHV mutated and unmutated CLL cases, as well as in the non-progressive (NP) and 
progressive (P) phase of the disease was detected using a commercial pAb in flow 
cytometric analyses (paper I). Furthermore, using own anti-ROR1 mAbs surface expression 
of ROR1 indicated a higher frequency of ROR1 in (P) than (NP) as well as in unmutated 
than mutated cases, respectively (paper III). In contrary to others showing no difference 
with (P) and (NP) disease [269, 332], we defined a clear difference between two subgroups 
of CLL patients with regard to ROR1 expression. One explanation for this might be they 
used anti-ROR1 pAb and in one of the studies [332] the antibody was conjugated giving a 
high frequency of staining of CLL cells (paper III). Moreover, own anti-ROR1 mAbs 
showed a statistically higher expression of ROR1 compared to the commercially available 
pAbs (paper IV). Collectively, these results together with a recent publication [332] might 
propose a diagnostic and/or prognostic role for ROR1 in CLL. In addition, the level of 
surface expression of ROR1 and the absence in normal blood leukocytes indicates that 
ROR1 might be a candidate structure for further evaluation for targeted therapy. 
Protein analyses by Western blots using pAbs against the N-terminal part of ROR1 
revealed a single band of 105 kDa (the full-length transcript of ROR1) in CLL patients [300, 
374]. Contrary to the N-terminal ab, a C-terminal ab revealed 2 bands of 105 and 130 kDa 
(paper I). Altered glycosylation might explain the difference. The 130 kDa band may 
represent the fully glycosylated variant of ROR1 and 105 the unglycosylated protein [375]. 
Posttranslational modifications (PTMs) are processes important for proper functioning of 
many proteins with glycosylation, phosphorylation and ubiquitination among the important 
PTMs of proteins. Recently, a publication has confirmed the presence of the glycosylated 
130 kDa band in CLL. In addition it was found that ROR1 is posttranslationally modified 
by glycosylation and mono-ubiquitination. These modifications regulate ROR1 localization 
and signaling and are highly variable among individual CLL patients [370].  
In addition to glycosylation, phosphorylation of ROR1 is probably one of the 
important PTMs regulating the functional activity of ROR1 in the CLL cells. 
Phosphorylation of RTKs, especially at tyrosine residues is a major mechanism for 
regulation of different cellular processes including cell division, protein synthesis and 
transcriptional regulation [299, 376].  
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The preliminary observation that ROR1 is constitutively phosphorylated in CLL (data 
to be published) indicates that this RTK might be involved in the pathobiology of CLL. 
Additionally a significant correlation was found between progressive stage of CLL and 
phosphorylation of ROR1 (data to be published). 
Further investigation of the trio, Wnt signaling proteins-specially Wnt5a, ROR 
receptors-particularly ROR1 and STAT proteins-mainly STAT3, seems to be a logical 
approach to know the hidden aspects of their interaction with one another, to decode the 
unknown events of ROR1 signaling pathway and to understand the impact this might have 
on CLL pathobiology. 
6.2 FUNCTIONAL STUDIES OF ROR1 
The discovery of molecules uniquely overexpressed by malignant cells and critical for the 
growth and survival of the cancerous cells are crucial in defining new therapeutic 
strategies in human cancers. Dysregulation of kinases and phosphatases, which under 
normal conditions control the reversible process of phosphorylation, occurs in many 
diseases including cancer.  
The functional role of the kinase and phosphatase component of the human genome in 
apoptosis is poorly understood and entails the identification of new cell survival regulators 
and drug targets. For this purpose and to identify these kinases and phosphatases crucial to 
the survival of cancer cells, a high-throughput RNAi screening was utilized [377]. In the 
screen, 650 known and putative kinases were targeted by RNAi in HeLa cervival 
carcinoma cells. Of the 73 genes that were overall identified as survival kinases, ROR1 was 
one of four most potent. A greater than three fold increase in apoptosis was noted in HeLa 
cells, 72 h after silencing of ROR1.  
Based on the results from the RNAi study, we wanted to investigate the role of ROR1 
in the survival of CLL cells by using siRNAs specifically silencing the gene (paper II). The 
treatment of CLL cells by specific ROR1 siRNAs induced reduction of ROR1 mRNA 
expression. Additionally, Western blot analysis demonstrated that ROR1 protein was also 
downregulated 48 h after siRNA treatment. The outcome of silencing of ROR1 was a 
statistically significant apoptosis of CLL cells but not of B cells from normal donors. 
Overall our results of siRNA downregulation of ROR1 in CLL cells together with the 
RNAi screening, suggested that ROR1 is an important survival kinase in cancer and can be 
utilized as a target for therapeutic approaches. 
The current mAb therapy of CLL includes rituximab (anti-CD20), ofatumumab (anti-
CD20) and alemtuzumab (anti-CD52) [378]. Even though antibody therapy increases 
progression-free survival and overall survival of CLL patients, the widespread expression 
of these antigens on normal B, T and NK cells in addition to monocytes, may elicit 
complications such as hepatitis B virus reactivation and cytomegalovirus (CMV) 
reactivation following rituximab and alemtuzumab administration, respectively [379, 380].  
The important features of surface antigens for a successful mAb therapy include a 
restricted, uniform and constitutive cell surface expression [381, 382]. Additionally, three 
out of eleven mAbs approved for cancer therapy are indeed used in CLL treatment [383], 
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indicating that CLL is a preferred field with regard to antibody therapy [198]. Furthermore, 
CLL is a disease with availability of leukemic cells in circulation and also accessibility of 
mediators of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC). The structure of ROR1, consisting of extracellular and 
intracellular regions, also helps in designing targeted therapies in the form of antibody 
therapy or small molecule inhibitors.  
ROR1 appeared to meet most of these criteria, as a restricted and constitutive high 
expression was detected in all CLL patients tested with no expression of ROR1 in normal 
peripheral blood leukocytes [384]. Moreover, these results gave us a strong incentive for 
generating anti-ROR1 monoclonal antibodies for diagnostic purposes and the first step 
towards targeted therapy of CLL.  
For the same reason and in order to explore functionally suitable ROR1 epitopes for 
generation of human ROR1 mAbs for clinical trials and also to investigate the apoptotic 
effects of monoclonal antibodies on CLL cells in vitro, five mouse mAbs were generated.  
These mAbs were raised against peptides of extracellular Ig, CRD and KNG domains 
of ROR1. Interestingly, individual CLL patients showed a variance in the staining pattern 
by the different ROR1 mAbs. This might suggest a structural heterogeneity in the ROR1 
expression. Studies have shown a direct correlation between increased expression of RTK 
on tumor cells to higher proliferative potential and/or survival advantage of the tumor cells, 
indicating a poor clinical prognosis as well [215, 236]. In our study we observed that CLL 
patients follow the same pattern, with progressive patients having a higher frequency of 
ROR1 positive cells than those with non-progressive disease. A similar higher expression 
of ROR1 occurred in patients with unmutated IGHV genes compared to the mutated ones.  
Three functional assays i.e. direct induction of apoptosis, cross-linking of the surface 
bound ROR1 mAbs as well as complement in lysis were utilized and compared with 
murine and chimeric anti-CD20 (rituximab) mAbs, respectively. ROR1 mAbs were capable 
of inducing apoptosis. Different antibodies varied in their percentages of apoptosis, these 
were discussed in result section. There was no clear correlation between ROR1 expression 
[(frequency and density) (MFI)] and apoptosis (data not shown) and a similar phenomenon 
has been reported for mAbs against CD20 and RTKs [277, 385]. Moreover, antibodies alone 
against the CRD and KNG regions had the highest cytotoxic capability. This is an 
interesting observation as the CRD and KNG regions are presumed to contain Wnt family 
and non-Wnt-ligand binding modules involved in diverse cellular responses [11, 299, 305, 
386].  
These results provide the groundwork to further study ROR1 characterization in CLL 
patients and also calls for strategies to develop human mAbs that selectively target ROR1 
in CLL. It is predicted that such mAbs would facilitate a precise intervention without 
associated immune suppression. 
In addition to mAb therapy, ROR1 has also been shown to undergo apoptosis when 
targeted with specific small RTK inhibitor molecules (own unpublished data). In a recent 
study, CD8+ T cells have been engineered to express a ROR1-specific chimeric antigen 
receptor (CAR) that are able to recognize and lyse primary B CLL cells, but not normal B 
cells in vitro, suggesting the role of ROR1 molecule as a TAA and also using ROR1-
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specific T cell in treatment of CLL patients [321]. The role of ROR1, as a putative tumor 
associated antigen in active immunotherapy of CLL patients, has not been identified yet. In 
this regard and to explore the functional activity of CLL T cells against ROR1 molecule, 
the differences in the frequencies of activated T cells producing IFN-γ, IL-5, Il-17A and 
TGF-β in response to ROR1 peptides, in non-progressive versus progressive and IGHV 
mutated versus unmutated CLL patients, were investigated and compared to that of healthy 
controls (data to be published). 
6.3 ROR AND HEMATOLOGICAL MALIGNANCIES 
ROR family members (ROR1 and ROR2) have a similar structure consisting of a ligand 
binding extracellular part, a transmembrane part and an intracellular part with tyrosine 
kinase activity. Moreover, ROR1 and ROR2 are parts of the Wnt signaling pathway [305] 
and important for organogenesis during the embryonic stage [300, 301, 322, 325].  
Additionally, human ROR1 and ROR2 genes (hRor1 and hRor2) share an overall 58% 
identity in their amino acid sequence [300]. Furthermore previous publications have shown 
the gene expression of ROR1 in acute lymphocytic leukemia (ALL) patients [328, 329] and 
recently at the protein level in different types of non-Hodgkin lymphomas (NHL) [321, 330-
332] and in several solid tumors [333, 334].  
ROR2 on the other hand has been shown to be overexpressed in several solid tumors 
such as squamous cell carcinoma [345], malignant melanoma [346], osteosarcoma [347], 
renal cell carcinoma [348], prostate and gastric cancers [349, 350]. ROR2 was not detected in 
CLL and white blood cells of normal donors [269]. Mutations in the human ROR2 gene 
cause two well characterized skeletal defects, recessive Robinow syndrome (RRS) [335, 
336] and dominant brachydactyly B (BDB) [337, 338].  
Since there were no reports of ROR1 in malignancies of myeloid origins and also the 
fact that the expression pattern of ROR2 in hematological malignancies has not been 
investigated, we designed a study to find out more about the expression of ROR1 and 
ROR2 in hematological malignancies of lymphoid and myeloid origins. Our results 
indicated a significant variation in the expression of ROR1 in various hematological 
malignancies including CLL, MCL, MZL, DLBCL, FL, B-ALL, AML, CML and MM. 
Interestingly we could not detect ROR2 expression in any of the malignancies tested 
including CLL. There were no expressions of ROR1 and ROR2 in in PBMC of healthy 
donors.  
The exact reason for expression of ROR1 but not ROR2 in hematological malignancies 
is not known. One explanation might be the connection between Gamma interferon 
activation site (GAS) elements, STAT3 and ROR1 in hematological malignancies 
including CLL. Gamma interferon activation site (GAS) elements are short stretches of 
DNA-recognition motif in the promoter region of various genes [387]. It is reported that 
STAT3 activation results in binding of STAT3 to promoter region of target genes 
containing these DNA-recognition motifs (GAS elements) dramatically increasing the 
transcription of these genes [373]. We know that STAT3 is constitutively phosphorylated in 
CLL as well as in other hematologic malignancies [371, 373]. ROR1 promoter region 
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contain these GAS elements [372] while there are no reports indicating this for ROR2. 
Phosphorylated STAT3 by binding to the ROR1 promoter region (GAS elements) may 
cause activation of ROR1 leading to ROR1 protein production [372]. However, there are no 
reports indicating an association between STAT3, GAS elements and ROR2 in cancer.  
Another explanation might be that the level of hypo and hypermethylation in the 
promoter regions of ROR1 and ROR2 could be different. It is known that many kinases 
might be switched on or off by intracellular oxidation process. There is also a possibility 
that ROR1 activation could be triggered by reactive oxygen species (ROS) as has been 
shown for Axl activation in CLL [388]. CLL B cells compared to normal lymphocytes have 
increased reactive oxygen species [389]. 
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
Aberrant tyrosine kinase activation may increase the survival, proliferation and drug 
resistance of malignant cells. More than thirty of known receptor tyrosine kinases (RTKs) 
are implicated in different human malignancies [200, 219]. A gene profiling study pointed 
the way towards a connection between the ROR1 RTK and CLL [327].  
The results presented in this thesis can be divided into two main sections, 
characterization of ROR1 and ROR2 in CLL and other hematological malignancies (paper 
I and IV). Functional studies utilizing siRNA and mAbs for downregulation of the 
functional activity and apoptosis of CLL cells (paper II and III).  
Firstly we were able to show that ROR1 is overexpressed in CLL patients both at gene 
and protein levels but not in healthy donors. Next we reported a significant variation in the 
expression of ROR1 in a panel of hematological malignancies tested, both of lymphoid and 
myeloid origins. Contrary to ROR1, ROR2 was not detected in hematological malignancies 
tested. ROR1 expression was related to the activity of the disease. No expression of ROR1 
and ROR2 were noted in PBMC of healthy donors.  
Second part of results of this thesis focused on two functional studies of ROR1, siRNA 
downregulation and in vitro antibody treatment of leukemic B CLL cells. It was 
demonstrated that ROR1 could be downregulated at gene and protein levels by specific 
ROR1 siRNAs. Downregulation of ROR1 resulted in induction of apoptosis of ROR1 in 
CLL cells but not in healthy B and T cells, thus identifying ROR1 as a survival kinase in 
CLL cells. Moreover, we generated a panel of mouse anti-ROR1 mAbs against extracelluar 
regions of ROR1 including immunoglobulin (Ig), cysteine-rich (CRD) and kringle (KNG) 
domains.  
These mAbs were capable of specifically recognizing cell surface expression of ROR1 
in CLL patients to a varying degree. Patients with progressive disease demonstrated a 
significantly higher proportion of ROR1 positive CLL cells as compared to non-
progressive patients. Furthermore, a significantly higher (p<0.05 – p<0.01) frequency of 
ROR1 positive cells was detected in unmutated CLL patients compared to the mutated 
CLL patients. These antibodies were also able to induce apoptosis of leukemic B cells of 
CLL patients in vitro compared to murine and chimeric anti-CD20 (rituximab) mAbs. 
Interestingly, anti-ROR1 CRD and KNG mAbs exhibited higher apoptosis induction, this 
was of particular importance as CRD and KNG regions are potential ligand binding sites of 
RTKs. Additionally, no relation between the frequency of ROR1 positive CLL cells and 
direct apoptosis was found.  
There is a constant need to improve therapy of CLL, especially with regard to mAb 
therapies, as such approaches seem to be safe and effective choices for treatment. We 
expect and foresee the generation and development of human antibodies against ROR1 for 
clinical trials using identified functional epitopes of ROR1 in CLL. Moreover, ROR1 
therapy may not only be restricted to CLL, in fact it has the potential of targeting other 
hematological malignancies as well as solid tumors. Furthermore, unique structure of 
ROR1 with an active kinase domain allows for other forms of targeted therapies such as 
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small RTK inhibitor molecules to be applied in future ROR1 positive malignancies. In 
addition to all the targeted therapeutic options, ROR1 can be potentially used in clinics for 
diagnosis and/or prognosis of CLL in near future. 
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